Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice
|
摘要
With the increasing number of individuals with diabetes and obesity,nonalcoholic fatty liver disease(NAFLD) is becoming increasingly prevalent,affecting one-quarter of adults worldwide. The spectrum of NAFLD ranges from simple steatosis or nonalcoholic fatty liver(NAFL) to nonalcoholic steatohepatitis(NASH). NAFLD, especially NASH, may progress to fibrosis, leading to cirrhosis and hepatocellular carcinoma. NAFLD can impose a severe economic burden,and patients with NAFLD-related terminal or deteriorative liver diseases have become one of the main groups receiving liver transplantation. The increasing prevalence of NAFLD and the severe outcomes of NASH make it necessary to use effective methods to identify NAFLD. Although recognized as the gold standard, biopsy is limited by its sampling bias, poor acceptability, and severe complications, such as mortality, bleeding, and pain. Therefore, noninvasive methods are urgently needed to avoid biopsy for diagnosing NAFLD. This review discusses the current noninvasive methods for assessing NAFLD,including steatosis, NASH, and NAFLD-related fibrosis, and explores the advantages and disadvantages of measurement tools. In addition, we analyze potential noninvasive biomarkers for tracking disease processes and monitoring treatment effects, and explore effective algorithms consisting of imaging and nonimaging biomarkers for diagnosing advanced fibrosis and reducing unnecessary biopsies in clinical practice.
With the increasing number of individuals with diabetes and obesity,nonalcoholic fatty liver disease(NAFLD) is becoming increasingly prevalent,affecting one-quarter of adults worldwide. The spectrum of NAFLD ranges from simple steatosis or nonalcoholic fatty liver(NAFL) to nonalcoholic steatohepatitis(NASH). NAFLD, especially NASH, may progress to fibrosis, leading to cirrhosis and hepatocellular carcinoma. NAFLD can impose a severe economic burden,and patients with NAFLD-related terminal or deteriorative liver diseases have become one of the main groups receiving liver transplantation. The increasing prevalence of NAFLD and the severe outcomes of NASH make it necessary to use effective methods to identify NAFLD. Although recognized as the gold standard, biopsy is limited by its sampling bias, poor acceptability, and severe complications, such as mortality, bleeding, and pain. Therefore, noninvasive methods are urgently needed to avoid biopsy for diagnosing NAFLD. This review discusses the current noninvasive methods for assessing NAFLD,including steatosis, NASH, and NAFLD-related fibrosis, and explores the advantages and disadvantages of measurement tools. In addition, we analyze potential noninvasive biomarkers for tracking disease processes and monitoring treatment effects, and explore effective algorithms consisting of imaging and nonimaging biomarkers for diagnosing advanced fibrosis and reducing unnecessary biopsies in clinical practice.
With the increasing number of individuals with diabetes and obesity,nonalcoholic fatty liver disease(NAFLD) is becoming increasingly prevalent,affecting one-quarter of adults worldwide. The spectrum of NAFLD ranges from simple steatosis or nonalcoholic fatty liver(NAFL) to nonalcoholic steatohepatitis(NASH). NAFLD, especially NASH, may progress to fibrosis, leading to cirrhosis and hepatocellular carcinoma. NAFLD can impose a severe economic burden,and patients with NAFLD-related terminal or deteriorative liver diseases have become one of the main groups receiving liver transplantation. The increasing prevalence of NAFLD and the severe outcomes of NASH make it necessary to use effective methods to identify NAFLD. Although recognized as the gold standard, biopsy is limited by its sampling bias, poor acceptability, and severe complications, such as mortality, bleeding, and pain. Therefore, noninvasive methods are urgently needed to avoid biopsy for diagnosing NAFLD. This review discusses the current noninvasive methods for assessing NAFLD,including steatosis, NASH, and NAFLD-related fibrosis, and explores the advantages and disadvantages of measurement tools. In addition, we analyze potential noninvasive biomarkers for tracking disease processes and monitoring treatment effects, and explore effective algorithms consisting of imaging and nonimaging biomarkers for diagnosing advanced fibrosis and reducing unnecessary biopsies in clinical practice.
引文
1 Younossi ZM,Koenig AB,Abdelatif D,Fazel Y,Henry L,Wymer M.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology 2016;64:73-84[PMID:26707365 DOI:10.1002/hep.28431]
2 Dai W,Ye L,Liu A,Wen SW,Deng J,Wu X,Lai Z.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus:A meta-analysis.Medicine(Baltimore)2017;96:e8179[PMID:28953675 DOI:10.1097/MD.0000000000008179]
3 Machado M,Marques-Vidal P,Cortez-Pinto H.Hepatic histology in obese patients undergoing bariatric surgery.J Hepatol 2006;45:600-606[PMID:16899321 DOI:10.1016/j.jhep.2006.06.013]
4 Mili?S,Luli?D,?timac D.Non-alcoholic fatty liver disease and obesity:biochemical,metabolic and clinical presentations.World J Gastroenterol 2014;20:9330-9337[PMID:25071327 DOI:10.3748/wjg.v20.i28.9330]
5 Estes C,Razavi H,Loomba R,Younossi Z,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology 2018;67:123-133[PMID:28802062 DOI:10.1002/hep.29466]
6 Li Z,Xue J,Chen P,Chen L,Yan S,Liu L.Prevalence of nonalcoholic fatty liver disease in mainland of China:a meta-analysis of published studies.J Gastroenterol Hepatol 2014;29:42-51[PMID:24219010DOI:10.1111/jgh.12428]
7 Almobarak AO,Barakat S,Khalifa MH,Elhoweris MH,Elhassan TM,Ahmed MH.Non alcoholic fatty liver disease(NAFLD)in a Sudanese population:What is the prevalence and risk factors?Arab JGastroenterol 2014;15:12-15[PMID:24630507 DOI:10.1016/j.ajg.2014.01.008]
8 Onyekwere CA,Ogbera AO,Balogun BO.Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community.Ann Hepatol 2011;10:119-124[PMID:21502672]
9 Eshraghian A,Dabbaghmanesh MH,Eshraghian H,Fattahi MR,Omrani GR.Nonalcoholic fatty liver disease in a cluster of Iranian population:thyroid status and metabolic risk factors.Arch Iran Med 2013;16:584-589[PMID:24093139]
10 Ji YX,Huang Z,Yang X,Wang X,Zhao LP,Wang PX,Zhang XJ,Alves-Bezerra M,Cai L,Zhang P,Lu YX,Bai L,Gao MM,Zhao H,Tian S,Wang Y,Huang ZX,Zhu XY,Zhang Y,Gong J,She ZG,Li F,Cohen DE,Li H.The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.Nat Med 2018;24:213-223[PMID:29291351 DOI:10.1038/nm.4461]
11 Younossi ZM,Blissett D,Blissett R,Henry L,Stepanova M,Younossi Y,Racila A,Hunt S,Beckerman R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology 2016;64:1577-1586[PMID:27543837 DOI:10.1002/hep.28785]
12 Zhang XJ,She ZG,Li H.Time to step-up the fight against NAFLD.Hepatology 2018;67:2068-2071[PMID:29451316 DOI:10.1002/hep.29845]
13 Perumpail BJ,Khan MA,Yoo ER,Cholankeril G,Kim D,Ahmed A.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:8263-8276[PMID:29307986DOI:10.3748/wjg.v23.i47.8263]
14 Wong RJ,Cheung R,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology 2014;59:2188-2195[PMID:24375711 DOI:10.1002/hep.26986]
15 Mikolasevic I,Filipec-Kanizaj T,Mijic M,Jakopcic I,Milic S,Hrstic I,Sobocan N,Stimac D,Burra P.Nonalcoholic fatty liver disease and liver transplantation-Where do we stand?World J Gastroenterol2018;24:1491-1506[PMID:29662288 DOI:10.3748/wjg.v24.i14.1491]
16 Lassailly G,Caiazzo R,Pattou F,Mathurin P.Perspectives on Treatment for Nonalcoholic Steatohepatitis.Gastroenterology 2016;150:1835-1848[PMID:26971824 DOI:10.1053/j.gastro.2016.03.004]
17 Rotman Y,Sanyal AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Gut2017;66:180-190[PMID:27646933 DOI:10.1136/gutjnl-2016-312431]
18 Xie L,Wang PX,Zhang P,Zhang XJ,Zhao GN,Wang A,Guo J,Zhu X,Zhang Q,Li H.DKK3expression in hepatocytes defines susceptibility to liver steatosis and obesity.J Hepatol 2016;65:113-124[PMID:27016281 DOI:10.1016/j.jhep.2016.03.008]
19 Yan FJ,Zhang XJ,Wang WX,Ji YX,Wang PX,Yang Y,Gong J,Shen LJ,Zhu XY,Huang Z,Li H.The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.Hepatology2017;65:1492-1511[PMID:27981609 DOI:10.1002/hep.28971]
20 Gao L,Wang PX,Zhang Y,Yu CJ,Ji Y,Wang X,Zhang P,Jiang X,Jin H,Huang Z,Zhang ZR,Li H.Tumor necrosis factor receptor-associated factor 5(Traf5)acts as an essential negative regulator of hepatic steatosis.J Hepatol 2016;65:125-136[PMID:27032381 DOI:10.1016/j.jhep.2016.03.006]
21 Cai J,Xu M,Zhang X,Li H.Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.Annu Rev Pathol 2019;14:153-184[PMID:30230967 DOI:10.1146/annurev-pathmechdis-012418-013003]
22 Wang XA,Zhang R,Zhang S,Deng S,Jiang D,Zhong J,Yang L,Wang T,Hong S,Guo S,She ZG,Zhang XD,Li H.Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance.Am J Physiol Endocrinol Metab 2013;305:E485-E495[PMID:23695216 DOI:10.1152/ajpendo.00505.2012]
23 Wang PX,Zhang XJ,Luo P,Jiang X,Zhang P,Guo J,Zhao GN,Zhu X,Zhang Y,Yang S,Li H.Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.Nat Commun 2016;7:10592[PMID:26882989 DOI:10.1038/ncomms10592]
24 Xu M,Liu PP,Li H.Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases.Physiol Rev 2019;99:893-948[PMID:30565509 DOI:10.1152/physrev.00065.2017]
25 Xiang M,Wang PX,Wang AB,Zhang XJ,Zhang Y,Zhang P,Mei FH,Chen MH,Li H.Targeting hepatic TRAF1-ASK1 signaling to improve inflammation,insulin resistance,and hepatic steatosis.JHepatol 2016;64:1365-1377[PMID:26860405 DOI:10.1016/j.jhep.2016.02.002]
26 Eshraghian A.Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.World J Gastroenterol 2017;23:7495-7504[PMID:29204050 DOI:10.3748/wjg.v23.i42.7495]
27 Kanda T,Matsuoka S,Yamazaki M,Shibata T,Nirei K,Takahashi H,Kaneko T,Fujisawa M,Higuchi T,Nakamura H,Matsumoto N,Yamagami H,Ogawa M,Imazu H,Kuroda K,Moriyama M.Apoptosis and non-alcoholic fatty liver diseases.World J Gastroenterol 2018;24:2661-2672[PMID:29991872 DOI:10.3748/wjg.v24.i25.2661]
28 Ekstedt M,Franzén LE,Mathiesen UL,Thorelius L,Holmqvist M,Bodemar G,Kechagias S.Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology 2006;44:865-873[PMID:17006923 DOI:10.1002/hep.21327]
29 Wong VW,Adams LA,de Lédinghen V,Wong GL,Sookoian S.Noninvasive biomarkers in NAFLD and NASH-current progress and future promise.Nat Rev Gastroenterol Hepatol 2018;15:461-478[PMID:29844588 DOI:10.1038/s41575-018-0014-9]
30 Merat S,Sotoudehmanesh R,Nouraie M,Peikan-Heirati M,Sepanlou SG,Malekzadeh R,Sotoudeh M.Sampling error in histopathology findings of nonalcoholic fatty liver disease:a post mortem liver histology study.Arch Iran Med 2012;15:418-421[PMID:22724878]
31 Cai J,Zhang XJ,Li H.Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.Med Res Rev 2019;39:328-348[PMID:29846945 DOI:10.1002/med.21515]
32 Pet?j?EM,Yki-J?rvinen H.Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.Int J Mol Sci 2016;17[PMID:27128911 DOI:10.3390/ijms17050633]
33 Roldan-Valadez E,Favila R,Martínez-López M,Uribe M,Ríos C,Méndez-Sánchez N.In vivo 3Tspectroscopic quantification of liver fat content in nonalcoholic fatty liver disease:Correlation with biochemical method and morphometry.J Hepatol 2010;53:732-737[PMID:20594607 DOI:10.1016/j.jhep.2010.04.018]
34 Kotronen A,Johansson LE,Johansson LM,Roos C,Westerbacka J,Hamsten A,Bergholm R,Arkkila P,Arola J,Kiviluoto T,Fisher RM,Ehrenborg E,Orho-Melander M,Ridderstr?le M,Groop L,Yki-J?rvinen H.A common variant in PNPLA3,which encodes adiponutrin,is associated with liver fat content in humans.Diabetologia 2009;52:1056-1060[PMID:19224197 DOI:10.1007/s00125-009-1285-z]
35 European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASOClinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol 2016;64:1388-1402[PMID:27062661 DOI:10.1016/j.jhep.2015.11.004]
36 Chalasani N,Younossi Z,Lavine JE,Charlton M,Cusi K,Rinella M,Harrison SA,Brunt EM,Sanyal AJ.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases.Hepatology 2018;67:328-357[PMID:28714183 DOI:10.1002/hep.29367]
37 Bedogni G,Bellentani S,Miglioli L,Masutti F,Passalacqua M,Castiglione A,Tiribelli C.The Fatty Liver Index:a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol2006;6:33[PMID:17081293 DOI:10.1186/1471-230x-6-33]
38 Fedchuk L,Nascimbeni F,Pais R,Charlotte F,Housset C,Ratziu V;LIDO Study Group.Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther 2014;40:1209-1222[PMID:25267215 DOI:10.1111/apt.12963]
39 Kotronen A,Peltonen M,Hakkarainen A,Sevastianova K,Bergholm R,Johansson LM,Lundbom N,Rissanen A,Ridderstr?le M,Groop L,Orho-Melander M,Yki-J?rvinen H.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.Gastroenterology 2009;137:865-872[PMID:19524579 DOI:10.1053/j.gastro.2009.06.005]
40 Koot BG.van der Baan-Slootweg OH,Bohte AE,Nederveen AJ,van Werven JR,Tamminga-Smeulders CL,Merkus MP,Schaap FG,Jansen PL,Stoker J,Benninga MA.Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children.Obesity(Silver Spring)2013;21:583-590[PMID:23592667 DOI:10.1002/oby.20173]
41 Poynard T,Ratziu V,Naveau S,Thabut D,Charlotte F,Messous D,Capron D,Abella A,Massard J,Ngo Y,Munteanu M,Mercadier A,Manns M,Albrecht J.The diagnostic value of biomarkers(SteatoTest)for the prediction of liver steatosis.Comp Hepatol 2005;4:10[PMID:16375767 DOI:10.1186/1476-5926-4-10]
42 Zhou YJ,Zhou YF,Zheng JN,Liu WY,Van Poucke S,Zou TT,Zhang DC,Shen S,Shi KQ,Wang XD,Zheng MH.NAFL screening score:A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.Clin Chim Acta 2017;475:44-50[PMID:28964832 DOI:10.1016/j.cca.2017.09.020]
43 Fuyan S,Jing L,Wenjun C,Zhijun T,Weijing M,Suzhen W,Yongyong X.Fatty liver disease index:a simple screening tool to facilitate diagnosis of nonalcoholic fatty liver disease in the Chinese population.Dig Dis Sci 2013;58:3326-3334[PMID:23900558 DOI:10.1007/s10620-013-2774-y]
44 Zhu J,He M,Zhang Y,Li T,Liu Y,Xu Z,Chen W.Validation of simple indexes for nonalcoholic fatty liver disease in western China:a retrospective cross-sectional study.Endocr J 2018;65:373-381[PMID:29434074 DOI:10.1507/endocrj.EJ17-0466]
45 Zhang S,Du T,Zhang J,Lu H,Lin X,Xie J,Yang Y,Yu X.The triglyceride and glucose index(TyG)is an effective biomarker to identify nonalcoholic fatty liver disease.Lipids Health Dis 2017;16:15[PMID:28103934 DOI:10.1186/s12944-017-0409-6]
46 Hernaez R,Lazo M,Bonekamp S,Kamel I,Brancati FL,Guallar E,Clark JM.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver:a meta-analysis.Hepatology 2011;54:1082-1090[PMID:21618575 DOI:10.1002/hep.24452]
47 Xia MF,Yan HM,He WY,Li XM,Li CL,Yao XZ,Li RK,Zeng MS,Gao X.Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content:an improvement method.Obesity(Silver Spring)2012;20:444-452[PMID:22016092 DOI:10.1038/oby.2011.302]
48 Zhang B,Ding F,Chen T,Xia LH,Qian J,Lv GY.Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.World J Gastroenterol 2014;20:17985-17992[PMID:25548498DOI:10.3748/wjg.v20.i47.17985]
49 Xiao G,Zhu S,Xiao X,Yan L,Yang J,Wu G.Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis.Hepatology 2017;66:1486-1501[PMID:28586172 DOI:10.1002/hep.29302]
50 Park SH,Kim PN,Kim KW,Lee SW,Yoon SE,Park SW,Ha HK,Lee MG,Hwang S,Lee SG,Yu ES,Cho EY.Macrovesicular hepatic steatosis in living liver donors:use of CT for quantitative and qualitative assessment.Radiology 2006;239:105-112[PMID:16484355 DOI:10.1148/radiol.2391050361]
51 Kodama Y,Ng CS,Wu TT,Ayers GD,Curley SA,Abdalla EK,Vauthey JN,Charnsangavej C.Comparison of CT methods for determining the fat content of the liver.AJR Am J Roentgenol 2007;188:1307-1312[PMID:17449775 DOI:10.2214/ajr.06.0992]
52 Schwenzer NF,Springer F,Schraml C,Stefan N,Machann J,Schick F.Non-invasive assessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance.J Hepatol2009;51:433-445[PMID:19604596 DOI:10.1016/j.jhep.2009.05.023]
53 Panicek DM,Giess CS,Schwartz LH.Qualitative assessment of liver for fatty infiltration on contrastenhanced CT:is muscle a better standard of reference than spleen?J Comput Assist Tomogr 1997;21:699-705[PMID:9294555]
54 Ma X,Holalkere NS,Kambadakone R A,Mino-Kenudson M,Hahn PF,Sahani DV.Imaging-based quantification of hepatic fat:methods and clinical applications.Radiographics 2009;29:1253-1277[PMID:19755595 DOI:10.1148/rg.295085186]
55 Karlas T,Petroff D,Sasso M,Fan JG,Mi YQ,de Lédinghen V,Kumar M,Lupsor-Platon M,Han KH,Cardoso AC,Ferraioli G,Chan WK,Wong VW,Myers RP,Chayama K,Friedrich-Rust M,Beaugrand M,Shen F,Hiriart JB,Sarin SK,Badea R,Jung KS,Marcellin P,Filice C,Mahadeva S,Wong GL,Crotty P,Masaki K,Bojunga J,Bedossa P,Keim V,Wiegand J.Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis.J Hepatol 2017;66:1022-1030[PMID:28039099 DOI:10.1016/j.jhep.2016.12.022]
56 Chan WK,Nik Mustapha NR,Mahadeva S.Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2014;29:1470-1476[PMID:24548002 DOI:10.1111/jgh.12557]
57 Myers RP,Pomier-Layrargues G,Kirsch R,Pollett A,Duarte-Rojo A,Wong D,Beaton M,Levstik M,Crotty P,Elkashab M.Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients.Hepatology 2012;55:199-208[PMID:21898479 DOI:10.1002/hep.24624]
58 Chan WK,Nik Mustapha NR,Wong GL,Wong VW,Mahadeva S.Controlled attenuation parameter using the FibroScan?XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.United European Gastroenterol J 2017;5:76-85[PMID:28405325 DOI:10.1177/2050640616646528]
59 Springer F,Machann J,Claussen CD,Schick F,Schwenzer NF.Liver fat content determined by magnetic resonance imaging and spectroscopy.World J Gastroenterol 2010;16:1560-1566[PMID:20355234 DOI:10.3748/wjg.v16.i13.1560]
60 Dulai PS,Sirlin CB,Loomba R.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH:Clinical trials to clinical practice.J Hepatol 2016;65:1006-1016[PMID:27312947 DOI:10.1016/j.jhep.2016.06.005]
61 Tang A,Tan J,Sun M,Hamilton G,Bydder M,Wolfson T,Gamst AC,Middleton M,Brunt EM,Loomba R,Lavine JE,Schwimmer JB,Sirlin CB.Nonalcoholic fatty liver disease:MR imaging of liver proton density fat fraction to assess hepatic steatosis.Radiology 2013;267:422-431[PMID:23382291 DOI:10.1148/radiol.12120896]
62 Idilman IS,Aniktar H,Idilman R,Kabacam G,Savas B,Elhan A,Celik A,Bahar K,Karcaaltincaba M.Hepatic steatosis:quantification by proton density fat fraction with MR imaging versus liver biopsy.Radiology 2013;267:767-775[PMID:23382293 DOI:10.1148/radiol.13121360]
63 Bannas P,Kramer H,Hernando D,Agni R,Cunningham AM,Mandal R,Motosugi U,Sharma SD,Munoz del Rio A,Fernandez L,Reeder SB.Quantitative magnetic resonance imaging of hepatic steatosis:Validation in ex vivo human livers.Hepatology 2015;62:1444-1455[PMID:26224591 DOI:10.1002/hep.28012]
64 Reeder SB,Cruite I,Hamilton G,Sirlin CB.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy.J Magn Reson Imaging 2011;34:729-749[PMID:21928307 DOI:10.1002/jmri.22580]
65 Park CC,Nguyen P,Hernandez C,Bettencourt R,Ramirez K,Fortney L,Hooker J,Sy E,Savides MT,Alquiraish MH,Valasek MA,Rizo E,Richards L,Brenner D,Sirlin CB,Loomba R.Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.Gastroenterology 2017;152:598-607.e2[PMID:27911262 DOI:10.1053/j.gastro.2016.10.026]
66 Caussy C,Reeder SB,Sirlin CB,Loomba R.Noninvasive,Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.Hepatology 2018;68:763-772[PMID:29356032 DOI:10.1002/hep.29797]
67 Cassidy FH,Yokoo T,Aganovic L,Hanna RF,Bydder M,Middleton MS,Hamilton G,Chavez AD,Schwimmer JB,Sirlin CB.Fatty liver disease:MR imaging techniques for the detection and quantification of liver steatosis.Radiographics 2009;29:231-260[PMID:19168847 DOI:10.1148/rg.291075123]
68 Nasr P,Forsgren MF,Ignatova S,Dahlstr?m N,Cedersund G,Leinhard OD,Norén B,Ekstedt M,Lundberg P,Kechagias S.Using a 3%Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis,Based on Results From Histopathology Analysis.Gastroenterology 2017;153:53-55.e7[PMID:28286210 DOI:10.1053/j.gastro.2017.03.005]
69 Cowin GJ,Jonsson JR,Bauer JD,Ash S,Ali A,Osland EJ,Purdie DM,Clouston AD,Powell EE,Galloway GJ.Magnetic resonance imaging and spectroscopy for monitoring liver steatosis.J Magn Reson Imaging 2008;28:937-945[PMID:18821619 DOI:10.1002/jmri.21542]
70 Lee SS,Park SH,Kim HJ,Kim SY,Kim MY,Kim DY,Suh DJ,Kim KM,Bae MH,Lee JY,Lee SG,Yu ES.Non-invasive assessment of hepatic steatosis:prospective comparison of the accuracy of imaging examinations.J Hepatol 2010;52:579-585[PMID:20185194 DOI:10.1016/j.jhep.2010.01.008]
71 Kim HJ,Cho HJ,Kim B,You MW,Lee JH,Huh J,Kim JK.Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals:A phantom and human study.J Magn Reson Imaging 2018[PMID:30430684 DOI:10.1002/jmri.26575]
72 Liu CY,McKenzie CA,Yu H,Brittain JH,Reeder SB.Fat quantification with IDEAL gradient echo imaging:correction of bias from T(1)and noise.Magn Reson Med 2007;58:354-364[PMID:17654578DOI:10.1002/mrm.21301]
73 Yu H,McKenzie CA,Shimakawa A,Vu AT,Brau AC,Beatty PJ,Pineda AR,Brittain JH,Reeder SB.Multiecho reconstruction for simultaneous water-fat decomposition and T2*estimation.J Magn Reson Imaging 2007;26:1153-1161[PMID:17896369 DOI:10.1002/jmri.21090]
74 Yu H,Shimakawa A,McKenzie CA,Brodsky E,Brittain JH,Reeder SB.Multiecho water-fat separation and simultaneous R2*estimation with multifrequency fat spectrum modeling.Magn Reson Med 2008;60:1122-1134[PMID:18956464 DOI:10.1002/mrm.21737]
75 Lewis S,Dyvorne H,Cui Y,Taouli B.Diffusion-weighted imaging of the liver:techniques and applications.Magn Reson Imaging Clin N Am 2014;22:373-395[PMID:25086935 DOI:10.1016/j.mric.2014.04.009]
76 Taouli B,Koh DM.Diffusion-weighted MR imaging of the liver.Radiology 2010;254:47-66[PMID:20032142 DOI:10.1148/radiol.09090021]
77 Manning P,Murphy P,Wang K,Hooker J,Wolfson T,Middleton MS,Newton KP,Behling C,Awai HI,Durelle J,Paiz MN,Angeles JE,De La Pena D,McCutchan JA,Schwimmer JB,Sirlin CB.Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease:A MAGNETstudy.J Magn Reson Imaging 2017;46:1149-1158[PMID:28225568 DOI:10.1002/jmri.25663]
78 d'Assignies G,Ruel M,Khiat A,Lepanto L,Chagnon M,Kauffmann C,Tang A,Gaboury L,Boulanger Y.Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.Eur Radiol 2009;19:2033-2040[PMID:19280194 DOI:10.1007/s00330-009-1351-4]
79 Imajo K,Kessoku T,Honda Y,Tomeno W,Ogawa Y,Mawatari H,Fujita K,Yoneda M,Taguri M,Hyogo H,Sumida Y,Ono M,Eguchi Y,Inoue T,Yamanaka T,Wada K,Saito S,Nakajima A.Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.Gastroenterology 2016;150:626-637.e7[PMID:26677985DOI:10.1053/j.gastro.2015.11.048]
80 Verma S,Jensen D,Hart J,Mohanty SR.Predictive value of ALT levels for non-alcoholic steatohepatitis(NASH)and advanced fibrosis in non-alcoholic fatty liver disease(NAFLD).Liver Int 2013;33:1398-1405[PMID:23763360 DOI:10.1111/liv.12226]
81 He L,Deng L,Zhang Q,Guo J,Zhou J,Song W,Yuan F.Diagnostic Value of CK-18,FGF-21,and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease:A Systematic Review and Meta-Analysis.Biomed Res Int 2017;2017:9729107[PMID:28326329 DOI:10.1155/2017/9729107]
82 Anty R,Iannelli A,Patouraux S,Bonnafous S,Lavallard VJ,Senni-Buratti M,Amor IB,Staccini-Myx A,Saint-Paul MC,Berthier F,Huet PM,Le Marchand-Brustel Y,Gugenheim J,Gual P,Tran A.A new composite model including metabolic syndrome,alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.Aliment Pharmacol Ther 2010;32:1315-1322[PMID:21050233 DOI:10.1111/j.1365-2036.2010.04480.x]
83 Grigorescu M,Crisan D,Radu C,Grigorescu MD,Sparchez Z,Serban A.A novel pathophysiologicalbased panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis.J Physiol Pharmacol 2012;63:347-353[PMID:23070083]
84 Huang JF,Yeh ML,Huang CF,Huang CI,Tsai PC,Tai CM,Yang HL,Dai CY,Hsieh MH,Chen SC,Yu ML,Chuang WL.Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.PLoS One 2017;12:e0174394[PMID:28472039 DOI:10.1371/journal.pone.0174394]
85 Schulthess FT,Paroni F,Sauter NS,Shu L,Ribaux P,Haataja L,Strieter RM,Oberholzer J,King CC,Maedler K.CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.Cell Metab 2009;9:125-139[PMID:19187771 DOI:10.1016/j.cmet.2009.01.003]
86 Zhang X,Shen J,Man K,Chu ES,Yau TO,Sung JC,Go MY,Deng J,Lu L,Wong VW,Sung JJ,Farrell G,Yu J.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of nonalcoholic steatohepatitis.J Hepatol 2014;61:1365-1375[PMID:25048951 DOI:10.1016/j.jhep.2014.07.006]
87 Qi S,Xu D,Li Q,Xie N,Xia J,Huo Q,Li P,Chen Q,Huang S.Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis.Clin Chim Acta 2017;473:89-95[PMID:28842175 DOI:10.1016/j.cca.2017.08.022]
88 Shen J,Chan HL,Wong GL,Choi PC,Chan AW,Chan HY,Chim AM,Yeung DK,Chan FK,Woo J,Yu J,Chu WC,Wong VW.Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.J Hepatol 2012;56:1363-1370[PMID:22314419 DOI:10.1016/j.jhep.2011.12.025]
89 Tietge UJ,Schmidt HH,Schütz T,Dippe P,Lochs H,Pirlich M.Reduced plasma adiponectin in NASH:central obesity as an underestimated causative risk factor.Hepatology 2005;41:401;author reply 401-401;author reply 402[PMID:15660429 DOI:10.1002/hep.20546]
90 George DK,Goldwurm S,MacDonald GA,Cowley LL,Walker NI,Ward PJ,Jazwinska EC,Powell LW.Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.Gastroenterology 1998;114:311-318[PMID:9453491 DOI:10.1016/S0016-5085(98)70482-2]
91 Kalantar-Zadeh K,Rodriguez RA,Humphreys MH.Association between serum ferritin and measures of inflammation,nutrition and iron in haemodialysis patients.Nephrol Dial Transplant 2004;19:141-149[PMID:14671049 DOI:10.1093/ndt/gfg493]
92 Puljiz Z,Stimac D,Kovac D,Puljiz M,Bratani?A,Kovaci?V,Kardum D,Bonacin D,Hozo I.Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity.Coll Antropol2010;34 Suppl 1:33-37[PMID:20402293]
93 Canbakan B,Senturk H,Tahan V,Hatemi I,Balci H,Toptas T,Sonsuz A,Velet M,Aydin S,Dirican A,Ozgulle S,Ozbay G.Clinical,biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease.Acta Gastroenterol Belg 2007;70:277-284[PMID:18074737]
94 Yoneda M,Nozaki Y,Endo H,Mawatari H,Iida H,Fujita K,Yoneda K,Takahashi H,Kirikoshi H,Inamori M,Kobayashi N,Kubota K,Saito S,Maeyama S,Hotta K,Nakajima A.Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis(NASH)independent of HFEgene mutation.Dig Dis Sci 2010;55:808-814[PMID:19267193 DOI:10.1007/s10620-009-0771-y]
95 Sumida Y,Yoneda M,Hyogo H,Yamaguchi K,Ono M,Fujii H,Eguchi Y,Suzuki Y,Imai S,Kanemasa K,Fujita K,Chayama K,Yasui K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSG-NAFLD).A simple clinical scoring system using ferritin,fasting insulin,and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.JGastroenterol 2011;46:257-268[PMID:20842510 DOI:10.1007/s00535-010-0305-6]
96 Poynard T,Ratziu V,Charlotte F,Messous D,Munteanu M,Imbert-Bismut F,Massard J,Bonyhay L,Tahiri M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V;LIDO Study Group;CYTOL study group.Diagnostic value of biochemical markers(NashTest)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol 2006;6:34[PMID:17096854 DOI:10.1186/1471-230x-6-34]
97 Kleiner DE,Brunt EM,Van Natta M,Behling C,Contos MJ,Cummings OW,Ferrell LD,Liu YC,Torbenson MS,Unalp-Arida A,Yeh M,McCullough AJ,Sanyal AJ;Nonalcoholic Steatohepatitis Clinical Research Network.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005;41:1313-1321[PMID:15915461 DOI:10.1002/hep.20701]
98 Zhou Y,Ore?i?M,Leivonen M,Gopalacharyulu P,Hyysalo J,Arola J,Verrijken A,Francque S,Van Gaal L,Hy?tyl?inen T,Yki-J?rvinen H.Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites.Clin Gastroenterol Hepatol 2016;14:1463-1472.e6[PMID:27317851 DOI:10.1016/j.cgh.2016.05.046]
99 Hyysalo J,M?nnist?VT,Zhou Y,Arola J,K?rj?V,Leivonen M,Juuti A,Jaser N,Lallukka S,K?kel?P,Venesmaa S,Simonen M,Saltevo J,Moilanen L,Korpi-Hy?valti E,Kein?nen-Kiukaanniemi S,Oksa H,Orho-Melander M,Valenti L,Fargion S,Pihlajam?ki J,Peltonen M,Yki-J?rvinen H.A population-based study on the prevalence of NASH using scores validated against liver histology.J Hepatol 2014;60:839-846[PMID:24333862 DOI:10.1016/j.jhep.2013.12.009]
100 Tai CM,Yu ML,Tu HP,Huang CK,Hwang JC,Chuang WL.Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity.Surg Obes Relat Dis 2017;13:686-692[PMID:28089433 DOI:10.1016/j.soard.2016.11.028]
101 Chunming L,Jianhui S,Hongguang Z,Chunwu Q,Xiaoyun H,Lijun Y,Xuejun Y.The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.Turk J Gastroenterol 2015;26:408-416[PMID:26215061 DOI:10.5152/tjg.2015.6336]
102 Chen J,Talwalkar JA,Yin M,Glaser KJ,Sanderson SO,Ehman RL.Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.Radiology 2011;259:749-756[PMID:21460032 DOI:10.1148/radiol.11101942]
103 Kim TH,Jeong CW,Jun HY,Kim YR,Kim JY,Lee YH,Yoon KH.Noninvasive Differential Diagnosis of Liver Iron Contents in Nonalcoholic Steatohepatitis and Simple Steatosis Using Multiecho Dixon Magnetic Resonance Imaging.Acad Radiol 2018[PMID:30143402 DOI:10.1016/j.acra.2018.06.022]
104 Ferreira VM,Piechnik SK,Dall'Armellina E,Karamitsos TD,Francis JM,Choudhury RP,Friedrich MG,Robson MD,Neubauer S.Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy:a comparison to T2-weighted cardiovascular magnetic resonance.J Cardiovasc Magn Reson2012;14:42[PMID:22720998 DOI:10.1186/1532-429X-14-42]
105 Piechnik SK,Ferreira VM,Dall'Armellina E,Cochlin LE,Greiser A,Neubauer S,Robson MD.Shortened Modified Look-Locker Inversion recovery(ShMOLLI)for clinical myocardial T1-mapping at 1.5 and 3 Twithin a 9 heartbeat breathhold.J Cardiovasc Magn Reson 2010;12:69[PMID:21092095 DOI:10.1186/1532-429X-12-69]
106 Rial B,Robson MD,Neubauer S,Schneider JE.Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla.Magn Reson Med 2011;66:619-624[PMID:21721038 DOI:10.1002/mrm.23011]
107 Banerjee R,Pavlides M,Tunnicliffe EM,Piechnik SK,Sarania N,Philips R,Collier JD,Booth JC,Schneider JE,Wang LM,Delaney DW,Fleming KA,Robson MD,Barnes E,Neubauer S.Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease.J Hepatol 2014;60:69-77[PMID:24036007 DOI:10.1016/j.jhep.2013.09.002]
108 Eddowes PJ,McDonald N,Davies N,Semple SIK,Kendall TJ,Hodson J,Newsome PN,Flintham RB,Wesolowski R,Blake L,Duarte RV,Kelly CJ,Herlihy AH,Kelly MD,Olliff SP,Hübscher SG,Fallowfield JA,Hirschfield GM.Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2018;47:631-644[PMID:29271504 DOI:10.1111/apt.14469]
109 Zhang P,Wang PX,Zhao LP,Zhang X,Ji YX,Zhang XJ,Fang C,Lu YX,Yang X,Gao MM,Zhang Y,Tian S,Zhu XY,Gong J,Ma XL,Li F,Wang Z,Huang Z,She ZG,Li H.The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.Nat Med2018;24:84-94[PMID:29227477 DOI:10.1038/nm.4453]
110 Wang S,Yan ZZ,Yang X,An S,Zhang K,Qi Y,Zheng J,Ji YX,Wang PX,Fang C,Zhu XY,Shen LJ,Yan FJ,Bao R,Tian S,She ZG,Tang YD.Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.Hepatology 2018;67:1320-1338[PMID:29077210 DOI:10.1002/hep.29616]
111 Zhao GN,Zhang P,Gong J,Zhang XJ,Wang PX,Yin M,Jiang Z,Shen LJ,Ji YX,Tong J,Wang Y,Wei QF,Wang Y,Zhu XY,Zhang X,Fang J,Xie Q,She ZG,Wang Z,Huang Z,Li H.Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.Nat Med 2017;23:742-752[PMID:28481357 DOI:10.1038/nm.4334]
112 Wang PX,Ji YX,Zhang XJ,Zhao LP,Yan ZZ,Zhang P,Shen LJ,Yang X,Fang J,Tian S,Zhu XY,Gong J,Zhang X,Wei QF,Wang Y,Li J,Wan L,Xie Q,She ZG,Wang Z,Huang Z,Li H.Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.Nat Med 2017;23:439-449[PMID:28218919 DOI:10.1038/nm.4290]
113 Zhu LH,Wang A,Luo P,Wang X,Jiang DS,Deng W,Zhang X,Wang T,Liu Y,Gao L,Zhang S,Zhang X,Zhang J,Li H.Mindin/Spondin 2 inhibits hepatic steatosis,insulin resistance,and obesity via interaction with peroxisome proliferator-activated receptorαin mice.J Hepatol 2014;60:1046-1054[PMID:24445216 DOI:10.1016/j.jhep.2014.01.011]
114 Liu XL,Pan Q,Zhang RN,Shen F,Yan SY,Sun C,Xu ZJ,Chen YW,Fan JG.Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.World J Gastroenterol 2016;22:9844-9852[PMID:27956809 DOI:10.3748/wjg.v22.i44.9844]
115 Liu CH.Ampuero J,Gil-Gómez A,Montero-Vallejo R,Rojasá,Mu?oz-Hernández R,Gallego-Durán R,Romero-Gómez M.miRNAs in patients with non-alcoholic fatty liver disease:A systematic review and meta-analysis.J Hepatol 2018;69:1335-1348[PMID:30142428 DOI:10.1016/j.jhep.2018.08.008]
116 Cermelli S,Ruggieri A,Marrero JA,Ioannou GN,Beretta L.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.PLoS One 2011;6:e23937[PMID:21886843DOI:10.1371/journal.pone.0023937]
117 Pirola CJ,Fernández Gianotti T,Casta?o GO,Mallardi P,San Martino J,Mora Gonzalez Lopez Ledesma M,Flichman D,Mirshahi F,Sanyal AJ,Sookoian S.Circulating microRNA signature in non-alcoholic fatty liver disease:from serum non-coding RNAs to liver histology and disease pathogenesis.Gut 2015;64:800-812[PMID:24973316 DOI:10.1136/gutjnl-2014-306996]
118 Becker PP,Rau M,Schmitt J,Malsch C,Hammer C,Bantel H,Müllhaupt B,Geier A.Performance of Serum microRNAs-122,-192 and-21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.PLoSOne 2015;10:e0142661[PMID:26565986 DOI:10.1371/journal.pone.0142661]
119 Van Berkel JJ,Dallinga JW,M?ller GM,Godschalk RW,Moonen EJ,Wouters EF,Van Schooten FJ.Aprofile of volatile organic compounds in breath discriminates COPD patients from controls.Respir Med2010;104:557-563[PMID:19906520 DOI:10.1016/j.rmed.2009.10.018]
120 Dallinga JW,Robroeks CM,van Berkel JJ,Moonen EJ,Godschalk RW,J?bsis Q,Dompeling E,Wouters EF,van Schooten FJ.Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children.Clin Exp Allergy 2010;40:68-76[PMID:19793086 DOI:10.1111/j.1365-2222.2009.03343.x]
121 Lang AL,Beier JI.Interaction of volatile organic compounds and underlying liver disease:a new paradigm for risk.Biol Chem 2018;399:1237-1248[PMID:29924722 DOI:10.1515/hsz-2017-0324]
122 Verdam FJ,Dallinga JW,Driessen A,de Jonge C,Moonen EJ,van Berkel JB,Luijk J,Bouvy ND,Buurman WA,Rensen SS,Greve JW,van Schooten FJ.Non-alcoholic steatohepatitis:a non-invasive diagnosis by analysis of exhaled breath.J Hepatol 2013;58:543-548[PMID:23142062 DOI:10.1016/j.jhep.2012.10.030]
123 Duarte SMB,Stefano JT,Miele L,Ponziani FR,Souza-Basqueira M,Okada LSRR,de Barros Costa FG,Toda K,Mazo DFC,Sabino EC,Carrilho FJ,Gasbarrini A,Oliveira CP.Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake:A prospective pilot study.Nutr Metab Cardiovasc Dis 2018;28:369-384[PMID:29482963 DOI:10.1016/j.numecd.2017.10.014]
124 Alonso C,Fernández-Ramos D,Varela-Rey M,Martínez-Arranz I,Navasa N,Van Liempd SM,Lavín Trueba JL,Mayo R,Ilisso CP,de Juan VG,Iruarrizaga-Lejarreta M,delaCruz-Villar L,MincholéI,Robinson A,Crespo J,Martín-Duce A,Romero-Gómez M,Sann H,Platon J,Van Eyk J,Aspichueta P,Noureddin M,Falcón-Pérez JM,Anguita J,Aransay AM,Martínez-Chantar ML,Lu SC,Mato JM.Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.Gastroenterology 2017;152:1449-1461.e7[PMID:28132890 DOI:10.1053/j.gastro.2017.01.015]
125 Soga T,Sugimoto M,Honma M,Mori M,Igarashi K,Kashikura K,Ikeda S,Hirayama A,Yamamoto T,Yoshida H,Otsuka M,Tsuji S,Yatomi Y,Sakuragawa T,Watanabe H,Nihei K,Saito T,Kawata S,Suzuki H,Tomita M,Suematsu M.Serum metabolomics revealsγ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease.J Hepatol 2011;55:896-905[PMID:21334394DOI:10.1016/j.jhep.2011.01.031]
126 Puri P,Wiest MM,Cheung O,Mirshahi F,Sargeant C,Min HK,Contos MJ,Sterling RK,Fuchs M,Zhou H,Watkins SM,Sanyal AJ.The plasma lipidomic signature of nonalcoholic steatohepatitis.Hepatology2009;50:1827-1838[PMID:19937697 DOI:10.1002/hep.23229]
127 Hagstr?m H,Nasr P,Ekstedt M,Hammar U,St?l P,Hultcrantz R,Kechagias S.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.JHepatol 2017;67:1265-1273[PMID:28803953 DOI:10.1016/j.jhep.2017.07.027]
128 Polyzos SA,Slavakis A,Koumerkeridis G,Katsinelos P,Kountouras J.Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease:An External Validation Cohort.Horm Metab Res 2019;51:134-140[PMID:30273934 DOI:10.1055/a-0713-1330]
129 Hansen JF,Juul Nielsen M,Nystr?m K,Leeming DJ,Lagging M,Norkrans G,Brehm Christensen P,Karsdal M.PRO-C3:a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.Scand J Gastroenterol 2018;53:83-87[PMID:29069995 DOI:10.1080/00365521.2017.1392596]
130 Daniels SJ,Leeming DJ,Eslam M,Hashem AM,Nielsen MJ,Krag A,Karsdal MA,Grove JI,Guha IN,Kawaguchi T,Torimura T,McLeod D,Akiba J,Kaye P,de Boer B,Aithal GP,Adams LA,George J.ADAPT:An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis.Hepatology 2018[PMID:30014517 DOI:10.1002/hep.30163]
131 Suzuki A,Angulo P,Lymp J,Li D,Satomura S,Lindor K.Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.Liver Int 2005;25:779-786[PMID:15998429 DOI:10.1111/j.1478-3231.2005.01064.x]
132 Miele L,De Michele T,Marrone G,Antonietta IsgròM,Basile U,Cefalo C,Biolato M,Maria Vecchio F,Lodovico Rapaccini G,Gasbarrini A,Zuppi C,Grieco A.Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting.Int J Biol Markers 2017;32:e397-e402[PMID:28862712 DOI:10.5301/ijbm.5000292]
133 Wai CT,Greenson JK,Fontana RJ,Kalbfleisch JD,Marrero JA,Conjeevaram HS,Lok AS.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology 2003;38:518-526[PMID:12883497 DOI:10.1053/jhep.2003.50346]
134 Sterling RK,Lissen E,Clumeck N,Sola R,Correa MC,Montaner J,S Sulkowski M,Torriani FJ,Dieterich DT,Thomas DL,Messinger D,Nelson M;APRICOT Clinical Investigators.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology2006;43:1317-1325[PMID:16729309 DOI:10.1002/hep.21178]
135 McPherson S,Stewart SF,Henderson E,Burt AD,Day CP.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut 2010;59:1265-1269[PMID:20801772 DOI:10.1136/gut.2010.216077]
136 McPherson S,Hardy T,Dufour JF,Petta S,Romero-Gomez M,Allison M,Oliveira CP,Francque S,Van Gaal L,Schattenberg JM,Tiniakos D,Burt A,Bugianesi E,Ratziu V,Day CP,Anstee QM.Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Am JGastroenterol 2017;112:740-751[PMID:27725647 DOI:10.1038/ajg.2016.453]
137 Ishiba H,Sumida Y,Tanaka S,Yoneda M,Hyogo H,Ono M,Fujii H,Eguchi Y,Suzuki Y,Yoneda M,Takahashi H,Nakahara T,Seko Y,Mori K,Kanemasa K,Shimada K,Imai S,Imajo K,Kawaguchi T,Nakajima A,Chayama K,Saibara T,Shima T,Fujimoto K,Okanoue T,Itoh Y;Japan Study Group of Non-Alcoholic Fatty Liver Disease(JSG-NAFLD).The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD:a multi-center study.J Gastroenterol 2018;53:1216-1224[PMID:29744597 DOI:10.1007/s00535-018-1474-y]
138 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
139 Harrison SA,Oliver D,Arnold HL,Gogia S,Neuschwander-Tetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
140 Fujii H,Enomoto M,Fukushima W,Tamori A,Sakaguchi H,Kawada N.Applicability of BARD score to Japanese patients with NAFLD.Gut 2009;58:1566-7;author reply 1567[PMID:19834122 DOI:10.1136/gut.2009.182758]
141 Wong VW,Vergniol J,Wong GL,Foucher J,Chan HL,Le Bail B,Choi PC,Kowo M,Chan AW,Merrouche W,Sung JJ,de Lédinghen V.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.Hepatology 2010;51:454-462[PMID:20101745 DOI:10.1002/hep.23312]
142 de Lédinghen V,Vergniol J.Transient elastography(FibroScan).Gastroenterol Clin Biol 2008;32:58-67[PMID:18973847 DOI:10.1016/S0399-8320(08)73994-0]
143 Wong VW,Vergniol J,Wong GL,Foucher J,Chan AW,Chermak F,Choi PC,Merrouche W,Chu SH,Pesque S,Chan HL,de Lédinghen V.Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.Am J Gastroenterol 2012;107:1862-1871[PMID:23032979 DOI:10.1038/ajg.2012.331]
144 Loong TC,Wei JL,Leung JC,Wong GL,Shu SS,Chim AM,Chan AW,Choi PC,Tse YK,Chan HL,Wong VW.Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol 2017;32:1363-1369[PMID:27936280 DOI:10.1111/jgh.13671]
145 Leung VY,Shen J,Wong VW,Abrigo J,Wong GL,Chim AM,Chu SH,Chan AW,Choi PC,Ahuja AT,Chan HL,Chu WC.Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis Bcarriers:comparison of shear-wave elastography and transient elastography with liver biopsy correlation.Radiology 2013;269:910-918[PMID:23912619 DOI:10.1148/radiol.13130128]
146 Ferraioli G,Tinelli C,Dal Bello B,Zicchetti M,Filice G,Filice C;Liver Fibrosis Study Group.Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C:a pilot study.Hepatology 2012;56:2125-2133[PMID:22767302 DOI:10.1002/hep.25936]
147 Cassinotto C,Boursier J,de Lédinghen V,Lebigot J,Lapuyade B,Cales P,Hiriart JB,Michalak S,Bail BL,Cartier V,Mouries A,Oberti F,Fouchard-Hubert I,Vergniol J,AubéC.Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging,FibroScan,and ARFI with liver biopsy.Hepatology 2016;63:1817-1827[PMID:26659452 DOI:10.1002/hep.28394]
148 Karagoz E,Ozturker C,Sonmez G.Noninvasive Evaluation of Liver Fibrosis:Supersonic Shear Imaging or Acoustic Radiation Force Impulse Imaging?Radiology 2016;279:979-980[PMID:27183412 DOI:10.1148/radiol.2016152532]
149 Friedrich-Rust M,Romen D,Vermehren J,Kriener S,Sadet D,Herrmann E,Zeuzem S,Bojunga J.Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.Eur J Radiol 2012;81:e325-e331[PMID:22119555 DOI:10.1016/j.ejrad.2011.10.029]
150 Liu H,Fu J,Hong R,Liu L,Li F.Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients:A Systematic Review&Meta-Analysis.PLoS One 2015;10:e0127782[PMID:26131717 DOI:10.1371/journal.pone.0127782]
151 Joo SK,Kim W,Kim D,Kim JH,Oh S,Lee KL,Chang MS,Jung YJ,So YH,Lee MS,Bae JM,Kim BG.Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.Liver Int 2018;38:331-341[PMID:28796410 DOI:10.1111/liv.13549]
152 Yanrong Guo.Haoming Lin,Xinyu Zhang,Huiying Wen,Siping Chen,Xin Chen.The influence of hepatic steatosis on the evaluation of fibrosis with non-alcoholic fatty liver disease by acoustic radiation force impulse.Conf Proc IEEE Eng Med Biol Soc 2017;2017:2988-2991[PMID:29060526 DOI:10.1109/EMBC.2017.8037485]
153 Wang QB,Zhu H,Liu HL,Zhang B.Performance of magnetic resonance elastography and diffusionweighted imaging for the staging of hepatic fibrosis:A meta-analysis.Hepatology 2012;56:239-247[PMID:22278368 DOI:10.1002/hep.25610]
154 Loomba R.Role of imaging-based biomarkers in NAFLD:Recent advances in clinical application and future research directions.J Hepatol 2018;68:296-304[PMID:29203392 DOI:10.1016/j.jhep.2017.11.028]
155 Doycheva I,Cui J,Nguyen P,Costa EA,Hooker J,Hofflich H,Bettencourt R,Brouha S,Sirlin CB,Loomba R.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRIand MRE.Aliment Pharmacol Ther 2016;43:83-95[PMID:26369383 DOI:10.1111/apt.13405]
156 Cui J,Ang B,Haufe W,Hernandez C,Verna EC,Sirlin CB,Loomba R.Comparative diagnostic accuracy of magnetic resonance elastography vs.eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease:a prospective study.Aliment Pharmacol Ther 2015;41:1271-1280[PMID:25873207 DOI:10.1111/apt.13196]
157 Yin M,Talwalkar JA,Glaser KJ,Manduca A,Grimm RC,Rossman PJ,Fidler JL,Ehman RL.Assessment of hepatic fibrosis with magnetic resonance elastography.Clin Gastroenterol Hepatol 2007;5:1207-1213.e2[PMID:17916548 DOI:10.1016/j.cgh.2007.06.012]
158 Venkatesh SK,Yin M,Ehman RL.Magnetic resonance elastography of liver:technique,analysis,and clinical applications.J Magn Reson Imaging 2013;37:544-555[PMID:23423795 DOI:10.1002/jmri.23731]
159 Singh S,Venkatesh SK,Loomba R,Wang Z,Sirlin C,Chen J,Yin M,Miller FH,Low RN,Hassanein T,Godfrey EM,Asbach P,Murad MH,Lomas DJ,Talwalkar JA,Ehman RL.Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease:a diagnostic accuracy systematic review and individual participant data pooled analysis.Eur Radiol 2016;26:1431-1440[PMID:26314479DOI:10.1007/s00330-015-3949-z]
160 Loomba R,Cui J,Wolfson T,Haufe W,Hooker J,Szeverenyi N,Ang B,Bhatt A,Wang K,Aryafar H,Behling C,Valasek MA,Lin GY,Gamst A,Brenner DA,Yin M,Glaser KJ,Ehman RL,Sirlin CB.Novel3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD:AProspective Study.Am J Gastroenterol 2016;111:986-994[PMID:27002798 DOI:10.1038/ajg.2016.65]
161 Cui J,Heba E,Hernandez C,Haufe W,Hooker J,Andre MP,Valasek MA,Aryafar H,Sirlin CB,Loomba R.Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease:A prospective study.Hepatology2016;63:453-461[PMID:26560734 DOI:10.1002/hep.28337]
162 Hardy T,Zeybel M,Day CP,Dipper C,Masson S,McPherson S,Henderson E,Tiniakos D,White S,French J,Mann DA,Anstee QM,Mann J.Plasma DNA methylation:a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Gut 2017;66:1321-1328[PMID:27002005 DOI:10.1136/gutjnl-2016-311526]
163 Pais R.Barritt AS 4th,Calmus Y,Scatton O,Runge T,Lebray P,Poynard T,Ratziu V,Conti F.NAFLDand liver transplantation:Current burden and expected challenges.J Hepatol 2016;65:1245-1257[PMID:27486010 DOI:10.1016/j.jhep.2016.07.033]
164 Ray K.NAFLD-the next global epidemic.Nat Rev Gastroenterol Hepatol 2013;10:621[PMID:24185985 DOI:10.1038/nrgastro.2013.197]
165 Singh S,Allen AM,Wang Z,Prokop LJ,Murad MH,Loomba R.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol 2015;13:643-654.e1-9;quiz e39-40[PMID:24768810 DOI:10.1016/j.cgh.2014.04.014]
166 Parkes J,Roderick P,Harris S,Day C,Mutimer D,Collier J,Lombard M,Alexander G,Ramage J,Dusheiko G,Wheatley M,Gough C,Burt A,Rosenberg W.Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.Gut 2010;59:1245-1251[PMID:20675693 DOI:10.1136/gut.2009.203166]
167 Sebastiani G,Alshaalan R,Wong P,Rubino M,Salman A,Metrakos P,Deschenes M,Ghali P.Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools,Hepatic Venous Pressure Gradient(HVPG)and Histology in Nonalcoholic Steatohepatitis.PLoS One 2015;10:e0128774[PMID:26083565 DOI:10.1371/journal.pone.0128774]
168 Boursier J,Vergniol J,Guillet A,Hiriart JB,Lannes A,Le Bail B,Michalak S,Chermak F,Bertrais S,Foucher J,Oberti F,Charbonnier M,Fouchard-Hubert I,Rousselet MC,Calès P,de Lédinghen V.Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.J Hepatol 2016;65:570-578[PMID:27151181 DOI:10.1016/j.jhep.2016.04.023]
169 Buckley AJ,Thomas EL,Lessan N,Trovato FM,Trovato GM,Taylor-Robinson SD.Non-alcoholic fatty liver disease:Relationship with cardiovascular risk markers and clinical endpoints.Diabetes Res Clin Pract 2018;144:144-152[PMID:30170074 DOI:10.1016/j.diabres.2018.08.011]
170 Trovato FM,Tognarelli JM,Crossey MM,Catalano D,Taylor-Robinson SD,Trovato GM.Challenges of liver cancer:Future emerging tools in imaging and urinary biomarkers.World J Hepatol 2015;7:2664-2675[PMID:26609343 DOI:10.4254/wjh.v7.i26.2664]
171 Sanyal AJ,Brunt EM,Kleiner DE,Kowdley KV,Chalasani N,Lavine JE,Ratziu V,McCullough A.Endpoints and clinical trial design for nonalcoholic steatohepatitis.Hepatology 2011;54:344-353[PMID:21520200 DOI:10.1002/hep.24376]
172 Middleton MS,Heba ER,Hooker CA,Bashir MR,Fowler KJ,Sandrasegaran K,Brunt EM,Kleiner DE,Doo E,Van Natta ML,Lavine JE,Neuschwander-Tetri BA,Sanyal A,Loomba R,Sirlin CB;NASHClinical Research Network.Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.Gastroenterology 2017;153:753-761[PMID:28624576 DOI:10.1053/j.gastro.2017.06.005]
173 Jayakumar S,Middleton MS,Lawitz EJ,Mantry PS,Caldwell SH,Arnold H,Mae Diehl A,Ghalib R,Elkhashab M,Abdelmalek MF,Kowdley KV,Stephen Djedjos C,Xu R,Han L,Mani Subramanian G,Myers RP,Goodman ZD,Afdhal NH,Charlton MR,Sirlin CB,Loomba R.Longitudinal correlations between MRE,MRI-PDFF,and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib.J Hepatol 2019;70:133-141[PMID:30291868 DOI:10.1016/j.jhep.2018.09.024]
174 Wieckowska A,Feldstein AE.Diagnosis of nonalcoholic fatty liver disease:invasive versus noninvasive.Semin Liver Dis 2008;28:386-395[PMID:18956295 DOI:10.1055/s-0028-1091983]
175 Vilar-Gomez E,Calzadilla-Bertot L,Friedman SL,Gra-Oramas B,Gonzalez-Fabian L,Lazo-Del Vallin S,Diago M,Adams LA.Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.Liver Int 2017;37:1887-1896[PMID:28544769 DOI:10.1111/liv.13480]
2 Dai W,Ye L,Liu A,Wen SW,Deng J,Wu X,Lai Z.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus:A meta-analysis.Medicine(Baltimore)2017;96:e8179[PMID:28953675 DOI:10.1097/MD.0000000000008179]
3 Machado M,Marques-Vidal P,Cortez-Pinto H.Hepatic histology in obese patients undergoing bariatric surgery.J Hepatol 2006;45:600-606[PMID:16899321 DOI:10.1016/j.jhep.2006.06.013]
4 Mili?S,Luli?D,?timac D.Non-alcoholic fatty liver disease and obesity:biochemical,metabolic and clinical presentations.World J Gastroenterol 2014;20:9330-9337[PMID:25071327 DOI:10.3748/wjg.v20.i28.9330]
5 Estes C,Razavi H,Loomba R,Younossi Z,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology 2018;67:123-133[PMID:28802062 DOI:10.1002/hep.29466]
6 Li Z,Xue J,Chen P,Chen L,Yan S,Liu L.Prevalence of nonalcoholic fatty liver disease in mainland of China:a meta-analysis of published studies.J Gastroenterol Hepatol 2014;29:42-51[PMID:24219010DOI:10.1111/jgh.12428]
7 Almobarak AO,Barakat S,Khalifa MH,Elhoweris MH,Elhassan TM,Ahmed MH.Non alcoholic fatty liver disease(NAFLD)in a Sudanese population:What is the prevalence and risk factors?Arab JGastroenterol 2014;15:12-15[PMID:24630507 DOI:10.1016/j.ajg.2014.01.008]
8 Onyekwere CA,Ogbera AO,Balogun BO.Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community.Ann Hepatol 2011;10:119-124[PMID:21502672]
9 Eshraghian A,Dabbaghmanesh MH,Eshraghian H,Fattahi MR,Omrani GR.Nonalcoholic fatty liver disease in a cluster of Iranian population:thyroid status and metabolic risk factors.Arch Iran Med 2013;16:584-589[PMID:24093139]
10 Ji YX,Huang Z,Yang X,Wang X,Zhao LP,Wang PX,Zhang XJ,Alves-Bezerra M,Cai L,Zhang P,Lu YX,Bai L,Gao MM,Zhao H,Tian S,Wang Y,Huang ZX,Zhu XY,Zhang Y,Gong J,She ZG,Li F,Cohen DE,Li H.The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.Nat Med 2018;24:213-223[PMID:29291351 DOI:10.1038/nm.4461]
11 Younossi ZM,Blissett D,Blissett R,Henry L,Stepanova M,Younossi Y,Racila A,Hunt S,Beckerman R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology 2016;64:1577-1586[PMID:27543837 DOI:10.1002/hep.28785]
12 Zhang XJ,She ZG,Li H.Time to step-up the fight against NAFLD.Hepatology 2018;67:2068-2071[PMID:29451316 DOI:10.1002/hep.29845]
13 Perumpail BJ,Khan MA,Yoo ER,Cholankeril G,Kim D,Ahmed A.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:8263-8276[PMID:29307986DOI:10.3748/wjg.v23.i47.8263]
14 Wong RJ,Cheung R,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology 2014;59:2188-2195[PMID:24375711 DOI:10.1002/hep.26986]
15 Mikolasevic I,Filipec-Kanizaj T,Mijic M,Jakopcic I,Milic S,Hrstic I,Sobocan N,Stimac D,Burra P.Nonalcoholic fatty liver disease and liver transplantation-Where do we stand?World J Gastroenterol2018;24:1491-1506[PMID:29662288 DOI:10.3748/wjg.v24.i14.1491]
16 Lassailly G,Caiazzo R,Pattou F,Mathurin P.Perspectives on Treatment for Nonalcoholic Steatohepatitis.Gastroenterology 2016;150:1835-1848[PMID:26971824 DOI:10.1053/j.gastro.2016.03.004]
17 Rotman Y,Sanyal AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Gut2017;66:180-190[PMID:27646933 DOI:10.1136/gutjnl-2016-312431]
18 Xie L,Wang PX,Zhang P,Zhang XJ,Zhao GN,Wang A,Guo J,Zhu X,Zhang Q,Li H.DKK3expression in hepatocytes defines susceptibility to liver steatosis and obesity.J Hepatol 2016;65:113-124[PMID:27016281 DOI:10.1016/j.jhep.2016.03.008]
19 Yan FJ,Zhang XJ,Wang WX,Ji YX,Wang PX,Yang Y,Gong J,Shen LJ,Zhu XY,Huang Z,Li H.The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.Hepatology2017;65:1492-1511[PMID:27981609 DOI:10.1002/hep.28971]
20 Gao L,Wang PX,Zhang Y,Yu CJ,Ji Y,Wang X,Zhang P,Jiang X,Jin H,Huang Z,Zhang ZR,Li H.Tumor necrosis factor receptor-associated factor 5(Traf5)acts as an essential negative regulator of hepatic steatosis.J Hepatol 2016;65:125-136[PMID:27032381 DOI:10.1016/j.jhep.2016.03.006]
21 Cai J,Xu M,Zhang X,Li H.Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.Annu Rev Pathol 2019;14:153-184[PMID:30230967 DOI:10.1146/annurev-pathmechdis-012418-013003]
22 Wang XA,Zhang R,Zhang S,Deng S,Jiang D,Zhong J,Yang L,Wang T,Hong S,Guo S,She ZG,Zhang XD,Li H.Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance.Am J Physiol Endocrinol Metab 2013;305:E485-E495[PMID:23695216 DOI:10.1152/ajpendo.00505.2012]
23 Wang PX,Zhang XJ,Luo P,Jiang X,Zhang P,Guo J,Zhao GN,Zhu X,Zhang Y,Yang S,Li H.Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.Nat Commun 2016;7:10592[PMID:26882989 DOI:10.1038/ncomms10592]
24 Xu M,Liu PP,Li H.Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases.Physiol Rev 2019;99:893-948[PMID:30565509 DOI:10.1152/physrev.00065.2017]
25 Xiang M,Wang PX,Wang AB,Zhang XJ,Zhang Y,Zhang P,Mei FH,Chen MH,Li H.Targeting hepatic TRAF1-ASK1 signaling to improve inflammation,insulin resistance,and hepatic steatosis.JHepatol 2016;64:1365-1377[PMID:26860405 DOI:10.1016/j.jhep.2016.02.002]
26 Eshraghian A.Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.World J Gastroenterol 2017;23:7495-7504[PMID:29204050 DOI:10.3748/wjg.v23.i42.7495]
27 Kanda T,Matsuoka S,Yamazaki M,Shibata T,Nirei K,Takahashi H,Kaneko T,Fujisawa M,Higuchi T,Nakamura H,Matsumoto N,Yamagami H,Ogawa M,Imazu H,Kuroda K,Moriyama M.Apoptosis and non-alcoholic fatty liver diseases.World J Gastroenterol 2018;24:2661-2672[PMID:29991872 DOI:10.3748/wjg.v24.i25.2661]
28 Ekstedt M,Franzén LE,Mathiesen UL,Thorelius L,Holmqvist M,Bodemar G,Kechagias S.Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology 2006;44:865-873[PMID:17006923 DOI:10.1002/hep.21327]
29 Wong VW,Adams LA,de Lédinghen V,Wong GL,Sookoian S.Noninvasive biomarkers in NAFLD and NASH-current progress and future promise.Nat Rev Gastroenterol Hepatol 2018;15:461-478[PMID:29844588 DOI:10.1038/s41575-018-0014-9]
30 Merat S,Sotoudehmanesh R,Nouraie M,Peikan-Heirati M,Sepanlou SG,Malekzadeh R,Sotoudeh M.Sampling error in histopathology findings of nonalcoholic fatty liver disease:a post mortem liver histology study.Arch Iran Med 2012;15:418-421[PMID:22724878]
31 Cai J,Zhang XJ,Li H.Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.Med Res Rev 2019;39:328-348[PMID:29846945 DOI:10.1002/med.21515]
32 Pet?j?EM,Yki-J?rvinen H.Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.Int J Mol Sci 2016;17[PMID:27128911 DOI:10.3390/ijms17050633]
33 Roldan-Valadez E,Favila R,Martínez-López M,Uribe M,Ríos C,Méndez-Sánchez N.In vivo 3Tspectroscopic quantification of liver fat content in nonalcoholic fatty liver disease:Correlation with biochemical method and morphometry.J Hepatol 2010;53:732-737[PMID:20594607 DOI:10.1016/j.jhep.2010.04.018]
34 Kotronen A,Johansson LE,Johansson LM,Roos C,Westerbacka J,Hamsten A,Bergholm R,Arkkila P,Arola J,Kiviluoto T,Fisher RM,Ehrenborg E,Orho-Melander M,Ridderstr?le M,Groop L,Yki-J?rvinen H.A common variant in PNPLA3,which encodes adiponutrin,is associated with liver fat content in humans.Diabetologia 2009;52:1056-1060[PMID:19224197 DOI:10.1007/s00125-009-1285-z]
35 European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASOClinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol 2016;64:1388-1402[PMID:27062661 DOI:10.1016/j.jhep.2015.11.004]
36 Chalasani N,Younossi Z,Lavine JE,Charlton M,Cusi K,Rinella M,Harrison SA,Brunt EM,Sanyal AJ.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases.Hepatology 2018;67:328-357[PMID:28714183 DOI:10.1002/hep.29367]
37 Bedogni G,Bellentani S,Miglioli L,Masutti F,Passalacqua M,Castiglione A,Tiribelli C.The Fatty Liver Index:a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol2006;6:33[PMID:17081293 DOI:10.1186/1471-230x-6-33]
38 Fedchuk L,Nascimbeni F,Pais R,Charlotte F,Housset C,Ratziu V;LIDO Study Group.Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther 2014;40:1209-1222[PMID:25267215 DOI:10.1111/apt.12963]
39 Kotronen A,Peltonen M,Hakkarainen A,Sevastianova K,Bergholm R,Johansson LM,Lundbom N,Rissanen A,Ridderstr?le M,Groop L,Orho-Melander M,Yki-J?rvinen H.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.Gastroenterology 2009;137:865-872[PMID:19524579 DOI:10.1053/j.gastro.2009.06.005]
40 Koot BG.van der Baan-Slootweg OH,Bohte AE,Nederveen AJ,van Werven JR,Tamminga-Smeulders CL,Merkus MP,Schaap FG,Jansen PL,Stoker J,Benninga MA.Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children.Obesity(Silver Spring)2013;21:583-590[PMID:23592667 DOI:10.1002/oby.20173]
41 Poynard T,Ratziu V,Naveau S,Thabut D,Charlotte F,Messous D,Capron D,Abella A,Massard J,Ngo Y,Munteanu M,Mercadier A,Manns M,Albrecht J.The diagnostic value of biomarkers(SteatoTest)for the prediction of liver steatosis.Comp Hepatol 2005;4:10[PMID:16375767 DOI:10.1186/1476-5926-4-10]
42 Zhou YJ,Zhou YF,Zheng JN,Liu WY,Van Poucke S,Zou TT,Zhang DC,Shen S,Shi KQ,Wang XD,Zheng MH.NAFL screening score:A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.Clin Chim Acta 2017;475:44-50[PMID:28964832 DOI:10.1016/j.cca.2017.09.020]
43 Fuyan S,Jing L,Wenjun C,Zhijun T,Weijing M,Suzhen W,Yongyong X.Fatty liver disease index:a simple screening tool to facilitate diagnosis of nonalcoholic fatty liver disease in the Chinese population.Dig Dis Sci 2013;58:3326-3334[PMID:23900558 DOI:10.1007/s10620-013-2774-y]
44 Zhu J,He M,Zhang Y,Li T,Liu Y,Xu Z,Chen W.Validation of simple indexes for nonalcoholic fatty liver disease in western China:a retrospective cross-sectional study.Endocr J 2018;65:373-381[PMID:29434074 DOI:10.1507/endocrj.EJ17-0466]
45 Zhang S,Du T,Zhang J,Lu H,Lin X,Xie J,Yang Y,Yu X.The triglyceride and glucose index(TyG)is an effective biomarker to identify nonalcoholic fatty liver disease.Lipids Health Dis 2017;16:15[PMID:28103934 DOI:10.1186/s12944-017-0409-6]
46 Hernaez R,Lazo M,Bonekamp S,Kamel I,Brancati FL,Guallar E,Clark JM.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver:a meta-analysis.Hepatology 2011;54:1082-1090[PMID:21618575 DOI:10.1002/hep.24452]
47 Xia MF,Yan HM,He WY,Li XM,Li CL,Yao XZ,Li RK,Zeng MS,Gao X.Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content:an improvement method.Obesity(Silver Spring)2012;20:444-452[PMID:22016092 DOI:10.1038/oby.2011.302]
48 Zhang B,Ding F,Chen T,Xia LH,Qian J,Lv GY.Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.World J Gastroenterol 2014;20:17985-17992[PMID:25548498DOI:10.3748/wjg.v20.i47.17985]
49 Xiao G,Zhu S,Xiao X,Yan L,Yang J,Wu G.Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis.Hepatology 2017;66:1486-1501[PMID:28586172 DOI:10.1002/hep.29302]
50 Park SH,Kim PN,Kim KW,Lee SW,Yoon SE,Park SW,Ha HK,Lee MG,Hwang S,Lee SG,Yu ES,Cho EY.Macrovesicular hepatic steatosis in living liver donors:use of CT for quantitative and qualitative assessment.Radiology 2006;239:105-112[PMID:16484355 DOI:10.1148/radiol.2391050361]
51 Kodama Y,Ng CS,Wu TT,Ayers GD,Curley SA,Abdalla EK,Vauthey JN,Charnsangavej C.Comparison of CT methods for determining the fat content of the liver.AJR Am J Roentgenol 2007;188:1307-1312[PMID:17449775 DOI:10.2214/ajr.06.0992]
52 Schwenzer NF,Springer F,Schraml C,Stefan N,Machann J,Schick F.Non-invasive assessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance.J Hepatol2009;51:433-445[PMID:19604596 DOI:10.1016/j.jhep.2009.05.023]
53 Panicek DM,Giess CS,Schwartz LH.Qualitative assessment of liver for fatty infiltration on contrastenhanced CT:is muscle a better standard of reference than spleen?J Comput Assist Tomogr 1997;21:699-705[PMID:9294555]
54 Ma X,Holalkere NS,Kambadakone R A,Mino-Kenudson M,Hahn PF,Sahani DV.Imaging-based quantification of hepatic fat:methods and clinical applications.Radiographics 2009;29:1253-1277[PMID:19755595 DOI:10.1148/rg.295085186]
55 Karlas T,Petroff D,Sasso M,Fan JG,Mi YQ,de Lédinghen V,Kumar M,Lupsor-Platon M,Han KH,Cardoso AC,Ferraioli G,Chan WK,Wong VW,Myers RP,Chayama K,Friedrich-Rust M,Beaugrand M,Shen F,Hiriart JB,Sarin SK,Badea R,Jung KS,Marcellin P,Filice C,Mahadeva S,Wong GL,Crotty P,Masaki K,Bojunga J,Bedossa P,Keim V,Wiegand J.Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis.J Hepatol 2017;66:1022-1030[PMID:28039099 DOI:10.1016/j.jhep.2016.12.022]
56 Chan WK,Nik Mustapha NR,Mahadeva S.Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2014;29:1470-1476[PMID:24548002 DOI:10.1111/jgh.12557]
57 Myers RP,Pomier-Layrargues G,Kirsch R,Pollett A,Duarte-Rojo A,Wong D,Beaton M,Levstik M,Crotty P,Elkashab M.Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients.Hepatology 2012;55:199-208[PMID:21898479 DOI:10.1002/hep.24624]
58 Chan WK,Nik Mustapha NR,Wong GL,Wong VW,Mahadeva S.Controlled attenuation parameter using the FibroScan?XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.United European Gastroenterol J 2017;5:76-85[PMID:28405325 DOI:10.1177/2050640616646528]
59 Springer F,Machann J,Claussen CD,Schick F,Schwenzer NF.Liver fat content determined by magnetic resonance imaging and spectroscopy.World J Gastroenterol 2010;16:1560-1566[PMID:20355234 DOI:10.3748/wjg.v16.i13.1560]
60 Dulai PS,Sirlin CB,Loomba R.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH:Clinical trials to clinical practice.J Hepatol 2016;65:1006-1016[PMID:27312947 DOI:10.1016/j.jhep.2016.06.005]
61 Tang A,Tan J,Sun M,Hamilton G,Bydder M,Wolfson T,Gamst AC,Middleton M,Brunt EM,Loomba R,Lavine JE,Schwimmer JB,Sirlin CB.Nonalcoholic fatty liver disease:MR imaging of liver proton density fat fraction to assess hepatic steatosis.Radiology 2013;267:422-431[PMID:23382291 DOI:10.1148/radiol.12120896]
62 Idilman IS,Aniktar H,Idilman R,Kabacam G,Savas B,Elhan A,Celik A,Bahar K,Karcaaltincaba M.Hepatic steatosis:quantification by proton density fat fraction with MR imaging versus liver biopsy.Radiology 2013;267:767-775[PMID:23382293 DOI:10.1148/radiol.13121360]
63 Bannas P,Kramer H,Hernando D,Agni R,Cunningham AM,Mandal R,Motosugi U,Sharma SD,Munoz del Rio A,Fernandez L,Reeder SB.Quantitative magnetic resonance imaging of hepatic steatosis:Validation in ex vivo human livers.Hepatology 2015;62:1444-1455[PMID:26224591 DOI:10.1002/hep.28012]
64 Reeder SB,Cruite I,Hamilton G,Sirlin CB.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy.J Magn Reson Imaging 2011;34:729-749[PMID:21928307 DOI:10.1002/jmri.22580]
65 Park CC,Nguyen P,Hernandez C,Bettencourt R,Ramirez K,Fortney L,Hooker J,Sy E,Savides MT,Alquiraish MH,Valasek MA,Rizo E,Richards L,Brenner D,Sirlin CB,Loomba R.Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.Gastroenterology 2017;152:598-607.e2[PMID:27911262 DOI:10.1053/j.gastro.2016.10.026]
66 Caussy C,Reeder SB,Sirlin CB,Loomba R.Noninvasive,Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.Hepatology 2018;68:763-772[PMID:29356032 DOI:10.1002/hep.29797]
67 Cassidy FH,Yokoo T,Aganovic L,Hanna RF,Bydder M,Middleton MS,Hamilton G,Chavez AD,Schwimmer JB,Sirlin CB.Fatty liver disease:MR imaging techniques for the detection and quantification of liver steatosis.Radiographics 2009;29:231-260[PMID:19168847 DOI:10.1148/rg.291075123]
68 Nasr P,Forsgren MF,Ignatova S,Dahlstr?m N,Cedersund G,Leinhard OD,Norén B,Ekstedt M,Lundberg P,Kechagias S.Using a 3%Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis,Based on Results From Histopathology Analysis.Gastroenterology 2017;153:53-55.e7[PMID:28286210 DOI:10.1053/j.gastro.2017.03.005]
69 Cowin GJ,Jonsson JR,Bauer JD,Ash S,Ali A,Osland EJ,Purdie DM,Clouston AD,Powell EE,Galloway GJ.Magnetic resonance imaging and spectroscopy for monitoring liver steatosis.J Magn Reson Imaging 2008;28:937-945[PMID:18821619 DOI:10.1002/jmri.21542]
70 Lee SS,Park SH,Kim HJ,Kim SY,Kim MY,Kim DY,Suh DJ,Kim KM,Bae MH,Lee JY,Lee SG,Yu ES.Non-invasive assessment of hepatic steatosis:prospective comparison of the accuracy of imaging examinations.J Hepatol 2010;52:579-585[PMID:20185194 DOI:10.1016/j.jhep.2010.01.008]
71 Kim HJ,Cho HJ,Kim B,You MW,Lee JH,Huh J,Kim JK.Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals:A phantom and human study.J Magn Reson Imaging 2018[PMID:30430684 DOI:10.1002/jmri.26575]
72 Liu CY,McKenzie CA,Yu H,Brittain JH,Reeder SB.Fat quantification with IDEAL gradient echo imaging:correction of bias from T(1)and noise.Magn Reson Med 2007;58:354-364[PMID:17654578DOI:10.1002/mrm.21301]
73 Yu H,McKenzie CA,Shimakawa A,Vu AT,Brau AC,Beatty PJ,Pineda AR,Brittain JH,Reeder SB.Multiecho reconstruction for simultaneous water-fat decomposition and T2*estimation.J Magn Reson Imaging 2007;26:1153-1161[PMID:17896369 DOI:10.1002/jmri.21090]
74 Yu H,Shimakawa A,McKenzie CA,Brodsky E,Brittain JH,Reeder SB.Multiecho water-fat separation and simultaneous R2*estimation with multifrequency fat spectrum modeling.Magn Reson Med 2008;60:1122-1134[PMID:18956464 DOI:10.1002/mrm.21737]
75 Lewis S,Dyvorne H,Cui Y,Taouli B.Diffusion-weighted imaging of the liver:techniques and applications.Magn Reson Imaging Clin N Am 2014;22:373-395[PMID:25086935 DOI:10.1016/j.mric.2014.04.009]
76 Taouli B,Koh DM.Diffusion-weighted MR imaging of the liver.Radiology 2010;254:47-66[PMID:20032142 DOI:10.1148/radiol.09090021]
77 Manning P,Murphy P,Wang K,Hooker J,Wolfson T,Middleton MS,Newton KP,Behling C,Awai HI,Durelle J,Paiz MN,Angeles JE,De La Pena D,McCutchan JA,Schwimmer JB,Sirlin CB.Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease:A MAGNETstudy.J Magn Reson Imaging 2017;46:1149-1158[PMID:28225568 DOI:10.1002/jmri.25663]
78 d'Assignies G,Ruel M,Khiat A,Lepanto L,Chagnon M,Kauffmann C,Tang A,Gaboury L,Boulanger Y.Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.Eur Radiol 2009;19:2033-2040[PMID:19280194 DOI:10.1007/s00330-009-1351-4]
79 Imajo K,Kessoku T,Honda Y,Tomeno W,Ogawa Y,Mawatari H,Fujita K,Yoneda M,Taguri M,Hyogo H,Sumida Y,Ono M,Eguchi Y,Inoue T,Yamanaka T,Wada K,Saito S,Nakajima A.Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.Gastroenterology 2016;150:626-637.e7[PMID:26677985DOI:10.1053/j.gastro.2015.11.048]
80 Verma S,Jensen D,Hart J,Mohanty SR.Predictive value of ALT levels for non-alcoholic steatohepatitis(NASH)and advanced fibrosis in non-alcoholic fatty liver disease(NAFLD).Liver Int 2013;33:1398-1405[PMID:23763360 DOI:10.1111/liv.12226]
81 He L,Deng L,Zhang Q,Guo J,Zhou J,Song W,Yuan F.Diagnostic Value of CK-18,FGF-21,and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease:A Systematic Review and Meta-Analysis.Biomed Res Int 2017;2017:9729107[PMID:28326329 DOI:10.1155/2017/9729107]
82 Anty R,Iannelli A,Patouraux S,Bonnafous S,Lavallard VJ,Senni-Buratti M,Amor IB,Staccini-Myx A,Saint-Paul MC,Berthier F,Huet PM,Le Marchand-Brustel Y,Gugenheim J,Gual P,Tran A.A new composite model including metabolic syndrome,alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.Aliment Pharmacol Ther 2010;32:1315-1322[PMID:21050233 DOI:10.1111/j.1365-2036.2010.04480.x]
83 Grigorescu M,Crisan D,Radu C,Grigorescu MD,Sparchez Z,Serban A.A novel pathophysiologicalbased panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis.J Physiol Pharmacol 2012;63:347-353[PMID:23070083]
84 Huang JF,Yeh ML,Huang CF,Huang CI,Tsai PC,Tai CM,Yang HL,Dai CY,Hsieh MH,Chen SC,Yu ML,Chuang WL.Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.PLoS One 2017;12:e0174394[PMID:28472039 DOI:10.1371/journal.pone.0174394]
85 Schulthess FT,Paroni F,Sauter NS,Shu L,Ribaux P,Haataja L,Strieter RM,Oberholzer J,King CC,Maedler K.CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.Cell Metab 2009;9:125-139[PMID:19187771 DOI:10.1016/j.cmet.2009.01.003]
86 Zhang X,Shen J,Man K,Chu ES,Yau TO,Sung JC,Go MY,Deng J,Lu L,Wong VW,Sung JJ,Farrell G,Yu J.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of nonalcoholic steatohepatitis.J Hepatol 2014;61:1365-1375[PMID:25048951 DOI:10.1016/j.jhep.2014.07.006]
87 Qi S,Xu D,Li Q,Xie N,Xia J,Huo Q,Li P,Chen Q,Huang S.Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis.Clin Chim Acta 2017;473:89-95[PMID:28842175 DOI:10.1016/j.cca.2017.08.022]
88 Shen J,Chan HL,Wong GL,Choi PC,Chan AW,Chan HY,Chim AM,Yeung DK,Chan FK,Woo J,Yu J,Chu WC,Wong VW.Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.J Hepatol 2012;56:1363-1370[PMID:22314419 DOI:10.1016/j.jhep.2011.12.025]
89 Tietge UJ,Schmidt HH,Schütz T,Dippe P,Lochs H,Pirlich M.Reduced plasma adiponectin in NASH:central obesity as an underestimated causative risk factor.Hepatology 2005;41:401;author reply 401-401;author reply 402[PMID:15660429 DOI:10.1002/hep.20546]
90 George DK,Goldwurm S,MacDonald GA,Cowley LL,Walker NI,Ward PJ,Jazwinska EC,Powell LW.Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.Gastroenterology 1998;114:311-318[PMID:9453491 DOI:10.1016/S0016-5085(98)70482-2]
91 Kalantar-Zadeh K,Rodriguez RA,Humphreys MH.Association between serum ferritin and measures of inflammation,nutrition and iron in haemodialysis patients.Nephrol Dial Transplant 2004;19:141-149[PMID:14671049 DOI:10.1093/ndt/gfg493]
92 Puljiz Z,Stimac D,Kovac D,Puljiz M,Bratani?A,Kovaci?V,Kardum D,Bonacin D,Hozo I.Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity.Coll Antropol2010;34 Suppl 1:33-37[PMID:20402293]
93 Canbakan B,Senturk H,Tahan V,Hatemi I,Balci H,Toptas T,Sonsuz A,Velet M,Aydin S,Dirican A,Ozgulle S,Ozbay G.Clinical,biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease.Acta Gastroenterol Belg 2007;70:277-284[PMID:18074737]
94 Yoneda M,Nozaki Y,Endo H,Mawatari H,Iida H,Fujita K,Yoneda K,Takahashi H,Kirikoshi H,Inamori M,Kobayashi N,Kubota K,Saito S,Maeyama S,Hotta K,Nakajima A.Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis(NASH)independent of HFEgene mutation.Dig Dis Sci 2010;55:808-814[PMID:19267193 DOI:10.1007/s10620-009-0771-y]
95 Sumida Y,Yoneda M,Hyogo H,Yamaguchi K,Ono M,Fujii H,Eguchi Y,Suzuki Y,Imai S,Kanemasa K,Fujita K,Chayama K,Yasui K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSG-NAFLD).A simple clinical scoring system using ferritin,fasting insulin,and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.JGastroenterol 2011;46:257-268[PMID:20842510 DOI:10.1007/s00535-010-0305-6]
96 Poynard T,Ratziu V,Charlotte F,Messous D,Munteanu M,Imbert-Bismut F,Massard J,Bonyhay L,Tahiri M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V;LIDO Study Group;CYTOL study group.Diagnostic value of biochemical markers(NashTest)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol 2006;6:34[PMID:17096854 DOI:10.1186/1471-230x-6-34]
97 Kleiner DE,Brunt EM,Van Natta M,Behling C,Contos MJ,Cummings OW,Ferrell LD,Liu YC,Torbenson MS,Unalp-Arida A,Yeh M,McCullough AJ,Sanyal AJ;Nonalcoholic Steatohepatitis Clinical Research Network.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005;41:1313-1321[PMID:15915461 DOI:10.1002/hep.20701]
98 Zhou Y,Ore?i?M,Leivonen M,Gopalacharyulu P,Hyysalo J,Arola J,Verrijken A,Francque S,Van Gaal L,Hy?tyl?inen T,Yki-J?rvinen H.Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites.Clin Gastroenterol Hepatol 2016;14:1463-1472.e6[PMID:27317851 DOI:10.1016/j.cgh.2016.05.046]
99 Hyysalo J,M?nnist?VT,Zhou Y,Arola J,K?rj?V,Leivonen M,Juuti A,Jaser N,Lallukka S,K?kel?P,Venesmaa S,Simonen M,Saltevo J,Moilanen L,Korpi-Hy?valti E,Kein?nen-Kiukaanniemi S,Oksa H,Orho-Melander M,Valenti L,Fargion S,Pihlajam?ki J,Peltonen M,Yki-J?rvinen H.A population-based study on the prevalence of NASH using scores validated against liver histology.J Hepatol 2014;60:839-846[PMID:24333862 DOI:10.1016/j.jhep.2013.12.009]
100 Tai CM,Yu ML,Tu HP,Huang CK,Hwang JC,Chuang WL.Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity.Surg Obes Relat Dis 2017;13:686-692[PMID:28089433 DOI:10.1016/j.soard.2016.11.028]
101 Chunming L,Jianhui S,Hongguang Z,Chunwu Q,Xiaoyun H,Lijun Y,Xuejun Y.The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.Turk J Gastroenterol 2015;26:408-416[PMID:26215061 DOI:10.5152/tjg.2015.6336]
102 Chen J,Talwalkar JA,Yin M,Glaser KJ,Sanderson SO,Ehman RL.Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.Radiology 2011;259:749-756[PMID:21460032 DOI:10.1148/radiol.11101942]
103 Kim TH,Jeong CW,Jun HY,Kim YR,Kim JY,Lee YH,Yoon KH.Noninvasive Differential Diagnosis of Liver Iron Contents in Nonalcoholic Steatohepatitis and Simple Steatosis Using Multiecho Dixon Magnetic Resonance Imaging.Acad Radiol 2018[PMID:30143402 DOI:10.1016/j.acra.2018.06.022]
104 Ferreira VM,Piechnik SK,Dall'Armellina E,Karamitsos TD,Francis JM,Choudhury RP,Friedrich MG,Robson MD,Neubauer S.Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy:a comparison to T2-weighted cardiovascular magnetic resonance.J Cardiovasc Magn Reson2012;14:42[PMID:22720998 DOI:10.1186/1532-429X-14-42]
105 Piechnik SK,Ferreira VM,Dall'Armellina E,Cochlin LE,Greiser A,Neubauer S,Robson MD.Shortened Modified Look-Locker Inversion recovery(ShMOLLI)for clinical myocardial T1-mapping at 1.5 and 3 Twithin a 9 heartbeat breathhold.J Cardiovasc Magn Reson 2010;12:69[PMID:21092095 DOI:10.1186/1532-429X-12-69]
106 Rial B,Robson MD,Neubauer S,Schneider JE.Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla.Magn Reson Med 2011;66:619-624[PMID:21721038 DOI:10.1002/mrm.23011]
107 Banerjee R,Pavlides M,Tunnicliffe EM,Piechnik SK,Sarania N,Philips R,Collier JD,Booth JC,Schneider JE,Wang LM,Delaney DW,Fleming KA,Robson MD,Barnes E,Neubauer S.Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease.J Hepatol 2014;60:69-77[PMID:24036007 DOI:10.1016/j.jhep.2013.09.002]
108 Eddowes PJ,McDonald N,Davies N,Semple SIK,Kendall TJ,Hodson J,Newsome PN,Flintham RB,Wesolowski R,Blake L,Duarte RV,Kelly CJ,Herlihy AH,Kelly MD,Olliff SP,Hübscher SG,Fallowfield JA,Hirschfield GM.Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2018;47:631-644[PMID:29271504 DOI:10.1111/apt.14469]
109 Zhang P,Wang PX,Zhao LP,Zhang X,Ji YX,Zhang XJ,Fang C,Lu YX,Yang X,Gao MM,Zhang Y,Tian S,Zhu XY,Gong J,Ma XL,Li F,Wang Z,Huang Z,She ZG,Li H.The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.Nat Med2018;24:84-94[PMID:29227477 DOI:10.1038/nm.4453]
110 Wang S,Yan ZZ,Yang X,An S,Zhang K,Qi Y,Zheng J,Ji YX,Wang PX,Fang C,Zhu XY,Shen LJ,Yan FJ,Bao R,Tian S,She ZG,Tang YD.Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.Hepatology 2018;67:1320-1338[PMID:29077210 DOI:10.1002/hep.29616]
111 Zhao GN,Zhang P,Gong J,Zhang XJ,Wang PX,Yin M,Jiang Z,Shen LJ,Ji YX,Tong J,Wang Y,Wei QF,Wang Y,Zhu XY,Zhang X,Fang J,Xie Q,She ZG,Wang Z,Huang Z,Li H.Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.Nat Med 2017;23:742-752[PMID:28481357 DOI:10.1038/nm.4334]
112 Wang PX,Ji YX,Zhang XJ,Zhao LP,Yan ZZ,Zhang P,Shen LJ,Yang X,Fang J,Tian S,Zhu XY,Gong J,Zhang X,Wei QF,Wang Y,Li J,Wan L,Xie Q,She ZG,Wang Z,Huang Z,Li H.Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.Nat Med 2017;23:439-449[PMID:28218919 DOI:10.1038/nm.4290]
113 Zhu LH,Wang A,Luo P,Wang X,Jiang DS,Deng W,Zhang X,Wang T,Liu Y,Gao L,Zhang S,Zhang X,Zhang J,Li H.Mindin/Spondin 2 inhibits hepatic steatosis,insulin resistance,and obesity via interaction with peroxisome proliferator-activated receptorαin mice.J Hepatol 2014;60:1046-1054[PMID:24445216 DOI:10.1016/j.jhep.2014.01.011]
114 Liu XL,Pan Q,Zhang RN,Shen F,Yan SY,Sun C,Xu ZJ,Chen YW,Fan JG.Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.World J Gastroenterol 2016;22:9844-9852[PMID:27956809 DOI:10.3748/wjg.v22.i44.9844]
115 Liu CH.Ampuero J,Gil-Gómez A,Montero-Vallejo R,Rojasá,Mu?oz-Hernández R,Gallego-Durán R,Romero-Gómez M.miRNAs in patients with non-alcoholic fatty liver disease:A systematic review and meta-analysis.J Hepatol 2018;69:1335-1348[PMID:30142428 DOI:10.1016/j.jhep.2018.08.008]
116 Cermelli S,Ruggieri A,Marrero JA,Ioannou GN,Beretta L.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.PLoS One 2011;6:e23937[PMID:21886843DOI:10.1371/journal.pone.0023937]
117 Pirola CJ,Fernández Gianotti T,Casta?o GO,Mallardi P,San Martino J,Mora Gonzalez Lopez Ledesma M,Flichman D,Mirshahi F,Sanyal AJ,Sookoian S.Circulating microRNA signature in non-alcoholic fatty liver disease:from serum non-coding RNAs to liver histology and disease pathogenesis.Gut 2015;64:800-812[PMID:24973316 DOI:10.1136/gutjnl-2014-306996]
118 Becker PP,Rau M,Schmitt J,Malsch C,Hammer C,Bantel H,Müllhaupt B,Geier A.Performance of Serum microRNAs-122,-192 and-21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.PLoSOne 2015;10:e0142661[PMID:26565986 DOI:10.1371/journal.pone.0142661]
119 Van Berkel JJ,Dallinga JW,M?ller GM,Godschalk RW,Moonen EJ,Wouters EF,Van Schooten FJ.Aprofile of volatile organic compounds in breath discriminates COPD patients from controls.Respir Med2010;104:557-563[PMID:19906520 DOI:10.1016/j.rmed.2009.10.018]
120 Dallinga JW,Robroeks CM,van Berkel JJ,Moonen EJ,Godschalk RW,J?bsis Q,Dompeling E,Wouters EF,van Schooten FJ.Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children.Clin Exp Allergy 2010;40:68-76[PMID:19793086 DOI:10.1111/j.1365-2222.2009.03343.x]
121 Lang AL,Beier JI.Interaction of volatile organic compounds and underlying liver disease:a new paradigm for risk.Biol Chem 2018;399:1237-1248[PMID:29924722 DOI:10.1515/hsz-2017-0324]
122 Verdam FJ,Dallinga JW,Driessen A,de Jonge C,Moonen EJ,van Berkel JB,Luijk J,Bouvy ND,Buurman WA,Rensen SS,Greve JW,van Schooten FJ.Non-alcoholic steatohepatitis:a non-invasive diagnosis by analysis of exhaled breath.J Hepatol 2013;58:543-548[PMID:23142062 DOI:10.1016/j.jhep.2012.10.030]
123 Duarte SMB,Stefano JT,Miele L,Ponziani FR,Souza-Basqueira M,Okada LSRR,de Barros Costa FG,Toda K,Mazo DFC,Sabino EC,Carrilho FJ,Gasbarrini A,Oliveira CP.Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake:A prospective pilot study.Nutr Metab Cardiovasc Dis 2018;28:369-384[PMID:29482963 DOI:10.1016/j.numecd.2017.10.014]
124 Alonso C,Fernández-Ramos D,Varela-Rey M,Martínez-Arranz I,Navasa N,Van Liempd SM,Lavín Trueba JL,Mayo R,Ilisso CP,de Juan VG,Iruarrizaga-Lejarreta M,delaCruz-Villar L,MincholéI,Robinson A,Crespo J,Martín-Duce A,Romero-Gómez M,Sann H,Platon J,Van Eyk J,Aspichueta P,Noureddin M,Falcón-Pérez JM,Anguita J,Aransay AM,Martínez-Chantar ML,Lu SC,Mato JM.Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.Gastroenterology 2017;152:1449-1461.e7[PMID:28132890 DOI:10.1053/j.gastro.2017.01.015]
125 Soga T,Sugimoto M,Honma M,Mori M,Igarashi K,Kashikura K,Ikeda S,Hirayama A,Yamamoto T,Yoshida H,Otsuka M,Tsuji S,Yatomi Y,Sakuragawa T,Watanabe H,Nihei K,Saito T,Kawata S,Suzuki H,Tomita M,Suematsu M.Serum metabolomics revealsγ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease.J Hepatol 2011;55:896-905[PMID:21334394DOI:10.1016/j.jhep.2011.01.031]
126 Puri P,Wiest MM,Cheung O,Mirshahi F,Sargeant C,Min HK,Contos MJ,Sterling RK,Fuchs M,Zhou H,Watkins SM,Sanyal AJ.The plasma lipidomic signature of nonalcoholic steatohepatitis.Hepatology2009;50:1827-1838[PMID:19937697 DOI:10.1002/hep.23229]
127 Hagstr?m H,Nasr P,Ekstedt M,Hammar U,St?l P,Hultcrantz R,Kechagias S.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.JHepatol 2017;67:1265-1273[PMID:28803953 DOI:10.1016/j.jhep.2017.07.027]
128 Polyzos SA,Slavakis A,Koumerkeridis G,Katsinelos P,Kountouras J.Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease:An External Validation Cohort.Horm Metab Res 2019;51:134-140[PMID:30273934 DOI:10.1055/a-0713-1330]
129 Hansen JF,Juul Nielsen M,Nystr?m K,Leeming DJ,Lagging M,Norkrans G,Brehm Christensen P,Karsdal M.PRO-C3:a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.Scand J Gastroenterol 2018;53:83-87[PMID:29069995 DOI:10.1080/00365521.2017.1392596]
130 Daniels SJ,Leeming DJ,Eslam M,Hashem AM,Nielsen MJ,Krag A,Karsdal MA,Grove JI,Guha IN,Kawaguchi T,Torimura T,McLeod D,Akiba J,Kaye P,de Boer B,Aithal GP,Adams LA,George J.ADAPT:An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis.Hepatology 2018[PMID:30014517 DOI:10.1002/hep.30163]
131 Suzuki A,Angulo P,Lymp J,Li D,Satomura S,Lindor K.Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.Liver Int 2005;25:779-786[PMID:15998429 DOI:10.1111/j.1478-3231.2005.01064.x]
132 Miele L,De Michele T,Marrone G,Antonietta IsgròM,Basile U,Cefalo C,Biolato M,Maria Vecchio F,Lodovico Rapaccini G,Gasbarrini A,Zuppi C,Grieco A.Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting.Int J Biol Markers 2017;32:e397-e402[PMID:28862712 DOI:10.5301/ijbm.5000292]
133 Wai CT,Greenson JK,Fontana RJ,Kalbfleisch JD,Marrero JA,Conjeevaram HS,Lok AS.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology 2003;38:518-526[PMID:12883497 DOI:10.1053/jhep.2003.50346]
134 Sterling RK,Lissen E,Clumeck N,Sola R,Correa MC,Montaner J,S Sulkowski M,Torriani FJ,Dieterich DT,Thomas DL,Messinger D,Nelson M;APRICOT Clinical Investigators.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology2006;43:1317-1325[PMID:16729309 DOI:10.1002/hep.21178]
135 McPherson S,Stewart SF,Henderson E,Burt AD,Day CP.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut 2010;59:1265-1269[PMID:20801772 DOI:10.1136/gut.2010.216077]
136 McPherson S,Hardy T,Dufour JF,Petta S,Romero-Gomez M,Allison M,Oliveira CP,Francque S,Van Gaal L,Schattenberg JM,Tiniakos D,Burt A,Bugianesi E,Ratziu V,Day CP,Anstee QM.Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Am JGastroenterol 2017;112:740-751[PMID:27725647 DOI:10.1038/ajg.2016.453]
137 Ishiba H,Sumida Y,Tanaka S,Yoneda M,Hyogo H,Ono M,Fujii H,Eguchi Y,Suzuki Y,Yoneda M,Takahashi H,Nakahara T,Seko Y,Mori K,Kanemasa K,Shimada K,Imai S,Imajo K,Kawaguchi T,Nakajima A,Chayama K,Saibara T,Shima T,Fujimoto K,Okanoue T,Itoh Y;Japan Study Group of Non-Alcoholic Fatty Liver Disease(JSG-NAFLD).The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD:a multi-center study.J Gastroenterol 2018;53:1216-1224[PMID:29744597 DOI:10.1007/s00535-018-1474-y]
138 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
139 Harrison SA,Oliver D,Arnold HL,Gogia S,Neuschwander-Tetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
140 Fujii H,Enomoto M,Fukushima W,Tamori A,Sakaguchi H,Kawada N.Applicability of BARD score to Japanese patients with NAFLD.Gut 2009;58:1566-7;author reply 1567[PMID:19834122 DOI:10.1136/gut.2009.182758]
141 Wong VW,Vergniol J,Wong GL,Foucher J,Chan HL,Le Bail B,Choi PC,Kowo M,Chan AW,Merrouche W,Sung JJ,de Lédinghen V.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.Hepatology 2010;51:454-462[PMID:20101745 DOI:10.1002/hep.23312]
142 de Lédinghen V,Vergniol J.Transient elastography(FibroScan).Gastroenterol Clin Biol 2008;32:58-67[PMID:18973847 DOI:10.1016/S0399-8320(08)73994-0]
143 Wong VW,Vergniol J,Wong GL,Foucher J,Chan AW,Chermak F,Choi PC,Merrouche W,Chu SH,Pesque S,Chan HL,de Lédinghen V.Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.Am J Gastroenterol 2012;107:1862-1871[PMID:23032979 DOI:10.1038/ajg.2012.331]
144 Loong TC,Wei JL,Leung JC,Wong GL,Shu SS,Chim AM,Chan AW,Choi PC,Tse YK,Chan HL,Wong VW.Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol 2017;32:1363-1369[PMID:27936280 DOI:10.1111/jgh.13671]
145 Leung VY,Shen J,Wong VW,Abrigo J,Wong GL,Chim AM,Chu SH,Chan AW,Choi PC,Ahuja AT,Chan HL,Chu WC.Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis Bcarriers:comparison of shear-wave elastography and transient elastography with liver biopsy correlation.Radiology 2013;269:910-918[PMID:23912619 DOI:10.1148/radiol.13130128]
146 Ferraioli G,Tinelli C,Dal Bello B,Zicchetti M,Filice G,Filice C;Liver Fibrosis Study Group.Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C:a pilot study.Hepatology 2012;56:2125-2133[PMID:22767302 DOI:10.1002/hep.25936]
147 Cassinotto C,Boursier J,de Lédinghen V,Lebigot J,Lapuyade B,Cales P,Hiriart JB,Michalak S,Bail BL,Cartier V,Mouries A,Oberti F,Fouchard-Hubert I,Vergniol J,AubéC.Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging,FibroScan,and ARFI with liver biopsy.Hepatology 2016;63:1817-1827[PMID:26659452 DOI:10.1002/hep.28394]
148 Karagoz E,Ozturker C,Sonmez G.Noninvasive Evaluation of Liver Fibrosis:Supersonic Shear Imaging or Acoustic Radiation Force Impulse Imaging?Radiology 2016;279:979-980[PMID:27183412 DOI:10.1148/radiol.2016152532]
149 Friedrich-Rust M,Romen D,Vermehren J,Kriener S,Sadet D,Herrmann E,Zeuzem S,Bojunga J.Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.Eur J Radiol 2012;81:e325-e331[PMID:22119555 DOI:10.1016/j.ejrad.2011.10.029]
150 Liu H,Fu J,Hong R,Liu L,Li F.Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients:A Systematic Review&Meta-Analysis.PLoS One 2015;10:e0127782[PMID:26131717 DOI:10.1371/journal.pone.0127782]
151 Joo SK,Kim W,Kim D,Kim JH,Oh S,Lee KL,Chang MS,Jung YJ,So YH,Lee MS,Bae JM,Kim BG.Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.Liver Int 2018;38:331-341[PMID:28796410 DOI:10.1111/liv.13549]
152 Yanrong Guo.Haoming Lin,Xinyu Zhang,Huiying Wen,Siping Chen,Xin Chen.The influence of hepatic steatosis on the evaluation of fibrosis with non-alcoholic fatty liver disease by acoustic radiation force impulse.Conf Proc IEEE Eng Med Biol Soc 2017;2017:2988-2991[PMID:29060526 DOI:10.1109/EMBC.2017.8037485]
153 Wang QB,Zhu H,Liu HL,Zhang B.Performance of magnetic resonance elastography and diffusionweighted imaging for the staging of hepatic fibrosis:A meta-analysis.Hepatology 2012;56:239-247[PMID:22278368 DOI:10.1002/hep.25610]
154 Loomba R.Role of imaging-based biomarkers in NAFLD:Recent advances in clinical application and future research directions.J Hepatol 2018;68:296-304[PMID:29203392 DOI:10.1016/j.jhep.2017.11.028]
155 Doycheva I,Cui J,Nguyen P,Costa EA,Hooker J,Hofflich H,Bettencourt R,Brouha S,Sirlin CB,Loomba R.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRIand MRE.Aliment Pharmacol Ther 2016;43:83-95[PMID:26369383 DOI:10.1111/apt.13405]
156 Cui J,Ang B,Haufe W,Hernandez C,Verna EC,Sirlin CB,Loomba R.Comparative diagnostic accuracy of magnetic resonance elastography vs.eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease:a prospective study.Aliment Pharmacol Ther 2015;41:1271-1280[PMID:25873207 DOI:10.1111/apt.13196]
157 Yin M,Talwalkar JA,Glaser KJ,Manduca A,Grimm RC,Rossman PJ,Fidler JL,Ehman RL.Assessment of hepatic fibrosis with magnetic resonance elastography.Clin Gastroenterol Hepatol 2007;5:1207-1213.e2[PMID:17916548 DOI:10.1016/j.cgh.2007.06.012]
158 Venkatesh SK,Yin M,Ehman RL.Magnetic resonance elastography of liver:technique,analysis,and clinical applications.J Magn Reson Imaging 2013;37:544-555[PMID:23423795 DOI:10.1002/jmri.23731]
159 Singh S,Venkatesh SK,Loomba R,Wang Z,Sirlin C,Chen J,Yin M,Miller FH,Low RN,Hassanein T,Godfrey EM,Asbach P,Murad MH,Lomas DJ,Talwalkar JA,Ehman RL.Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease:a diagnostic accuracy systematic review and individual participant data pooled analysis.Eur Radiol 2016;26:1431-1440[PMID:26314479DOI:10.1007/s00330-015-3949-z]
160 Loomba R,Cui J,Wolfson T,Haufe W,Hooker J,Szeverenyi N,Ang B,Bhatt A,Wang K,Aryafar H,Behling C,Valasek MA,Lin GY,Gamst A,Brenner DA,Yin M,Glaser KJ,Ehman RL,Sirlin CB.Novel3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD:AProspective Study.Am J Gastroenterol 2016;111:986-994[PMID:27002798 DOI:10.1038/ajg.2016.65]
161 Cui J,Heba E,Hernandez C,Haufe W,Hooker J,Andre MP,Valasek MA,Aryafar H,Sirlin CB,Loomba R.Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease:A prospective study.Hepatology2016;63:453-461[PMID:26560734 DOI:10.1002/hep.28337]
162 Hardy T,Zeybel M,Day CP,Dipper C,Masson S,McPherson S,Henderson E,Tiniakos D,White S,French J,Mann DA,Anstee QM,Mann J.Plasma DNA methylation:a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Gut 2017;66:1321-1328[PMID:27002005 DOI:10.1136/gutjnl-2016-311526]
163 Pais R.Barritt AS 4th,Calmus Y,Scatton O,Runge T,Lebray P,Poynard T,Ratziu V,Conti F.NAFLDand liver transplantation:Current burden and expected challenges.J Hepatol 2016;65:1245-1257[PMID:27486010 DOI:10.1016/j.jhep.2016.07.033]
164 Ray K.NAFLD-the next global epidemic.Nat Rev Gastroenterol Hepatol 2013;10:621[PMID:24185985 DOI:10.1038/nrgastro.2013.197]
165 Singh S,Allen AM,Wang Z,Prokop LJ,Murad MH,Loomba R.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol 2015;13:643-654.e1-9;quiz e39-40[PMID:24768810 DOI:10.1016/j.cgh.2014.04.014]
166 Parkes J,Roderick P,Harris S,Day C,Mutimer D,Collier J,Lombard M,Alexander G,Ramage J,Dusheiko G,Wheatley M,Gough C,Burt A,Rosenberg W.Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.Gut 2010;59:1245-1251[PMID:20675693 DOI:10.1136/gut.2009.203166]
167 Sebastiani G,Alshaalan R,Wong P,Rubino M,Salman A,Metrakos P,Deschenes M,Ghali P.Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools,Hepatic Venous Pressure Gradient(HVPG)and Histology in Nonalcoholic Steatohepatitis.PLoS One 2015;10:e0128774[PMID:26083565 DOI:10.1371/journal.pone.0128774]
168 Boursier J,Vergniol J,Guillet A,Hiriart JB,Lannes A,Le Bail B,Michalak S,Chermak F,Bertrais S,Foucher J,Oberti F,Charbonnier M,Fouchard-Hubert I,Rousselet MC,Calès P,de Lédinghen V.Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.J Hepatol 2016;65:570-578[PMID:27151181 DOI:10.1016/j.jhep.2016.04.023]
169 Buckley AJ,Thomas EL,Lessan N,Trovato FM,Trovato GM,Taylor-Robinson SD.Non-alcoholic fatty liver disease:Relationship with cardiovascular risk markers and clinical endpoints.Diabetes Res Clin Pract 2018;144:144-152[PMID:30170074 DOI:10.1016/j.diabres.2018.08.011]
170 Trovato FM,Tognarelli JM,Crossey MM,Catalano D,Taylor-Robinson SD,Trovato GM.Challenges of liver cancer:Future emerging tools in imaging and urinary biomarkers.World J Hepatol 2015;7:2664-2675[PMID:26609343 DOI:10.4254/wjh.v7.i26.2664]
171 Sanyal AJ,Brunt EM,Kleiner DE,Kowdley KV,Chalasani N,Lavine JE,Ratziu V,McCullough A.Endpoints and clinical trial design for nonalcoholic steatohepatitis.Hepatology 2011;54:344-353[PMID:21520200 DOI:10.1002/hep.24376]
172 Middleton MS,Heba ER,Hooker CA,Bashir MR,Fowler KJ,Sandrasegaran K,Brunt EM,Kleiner DE,Doo E,Van Natta ML,Lavine JE,Neuschwander-Tetri BA,Sanyal A,Loomba R,Sirlin CB;NASHClinical Research Network.Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.Gastroenterology 2017;153:753-761[PMID:28624576 DOI:10.1053/j.gastro.2017.06.005]
173 Jayakumar S,Middleton MS,Lawitz EJ,Mantry PS,Caldwell SH,Arnold H,Mae Diehl A,Ghalib R,Elkhashab M,Abdelmalek MF,Kowdley KV,Stephen Djedjos C,Xu R,Han L,Mani Subramanian G,Myers RP,Goodman ZD,Afdhal NH,Charlton MR,Sirlin CB,Loomba R.Longitudinal correlations between MRE,MRI-PDFF,and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib.J Hepatol 2019;70:133-141[PMID:30291868 DOI:10.1016/j.jhep.2018.09.024]
174 Wieckowska A,Feldstein AE.Diagnosis of nonalcoholic fatty liver disease:invasive versus noninvasive.Semin Liver Dis 2008;28:386-395[PMID:18956295 DOI:10.1055/s-0028-1091983]
175 Vilar-Gomez E,Calzadilla-Bertot L,Friedman SL,Gra-Oramas B,Gonzalez-Fabian L,Lazo-Del Vallin S,Diago M,Adams LA.Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.Liver Int 2017;37:1887-1896[PMID:28544769 DOI:10.1111/liv.13480]